Friday, June 8

---

[ Top of page ]

 

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL

0016 E2A/PBX, T(1;19) IS THE PREDOMINANT TRANSLOCATION IN PRECURSOR- B PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EGYPT WITH NO SPECIAL ASSOCIATION WITH PRE B PHENOTYPE

A. Kamel, Y. El-Nahass, I. Sidhom, K. Girtman, H. Moussa, D. Yassin, N. El-Sharkawy, K. Shaaban, H. Hussein, S. Aboul-Naga, W. Zekry, E. Ebeid, M. Zamzam, A. El-Haddad, S. Shurtleff (NCI, Cairo University, Cairo, Egypt)

0017 ROLE OF ERYTHROPOIETIN RECEPTOR IN T(12;21) POSITIVE LEUKEMIA

R. Panzer-Grümayer, A. Inthal, G. Krapf, E. Csinady, D. Beck, O. Orel, G. Mann (Children's Cancer Research Institute, Vienna, Austria)

0018 FLOW CYTOMETRY ANALYSIS OF THE CO-EXPRESSION OF T- AND B-CELL MARKERS IN BLASTS FROM PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

G. Shubinsky, T. Yermiahu, M. Van den Akker, I. Dulman, I. Levy, J. Kapelushnik (Soroka University Medical Center, Beer Sheva, Israel)

0019 EPIGENETIC THERAPY WITH 5-AZACITIDINE IN A TREATMENT SCHEDULE OF FIVE DAYS EVERY 4 WEEKS INDUCES HEMATOLOGIC RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA REFRACTORY TO OR NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

H.K. Al-Ali, S. Schwind, R. Krahl, C. Becker, S. Leiblein, C. Mueller, D. Niederwieser (University of Leipzig, Leipzig, Germany)

0020 MRD BY MULTIPARAMETER FLOW CYTOMETRY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: PROGNOSTIC IMPACT OF EARLY RESPONSE PARAMETERS ON THE MRD-STATUS AT THE END OF INDUCTION PHASE I

R. Ratei, M. Dworzak, P. Rhein, G. Basso, M. Veltroni, G. Gaipa, M. Schrappe, W.-D. Ludwig, L. Karawajew (HELIOS klinikum Berlin Buch, Berlin, Germany)

0021 CYTOREDUCTION RATES ARE ASSOCIATED WITH BCL-2 PROTEIN EXPRESSION IN ALL BLASTS PERSISTING DURING INDUCTION THERAPY

P. Rhein, R. Ratei, R. Mitloehner, A. Moericke, C. Hagemeier, K. Seeger, R. Kirschner-Schwabe, R. Spang, M. Schrappe, W.-D. Ludwig, L. Karawajew (Robert-Rossle-Clinic, HELIOS, Charite, Berlin, Germany)

0022 DIFFERENTIAL EXPRESSION OF VALOSIN-CONTAINING PROTEIN (VCP, P97) IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS WITH AND WITHOUT GLUCOCORTICOID TREATMENT

N. von Neuhoff, S. Junk, G. Cario, N. Wittner, M. Schrappe, B. Schlegelberger, M. Lauten (Medical school Hanover, OE 5120, Hanover, Germany)

0023 SAFETY AND TOLERABILITY OF INTRATHECAL LIPOSOMAL CYTARABINE AS CNS PROPHYLAXIS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

P.N. Neumeister, M. Pfeilstöcker, W. Linkesch, A. Rohn (Division of Hematology, Graz, Austria)

0024 GENE EXPRESSION PROFILING IN E2A-PBX1-SILENCED T(1;19)+ LEUKEMIA CELLS

G. Casagrande, G. Basso (University of Padova, Padova, Italy)

0025 TOLERANCE TO METHOTREXATE THERAPY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA: IMPORTANCE OF GENETIC POLYMORPHISMS IN FOLATE METABOLIC PATHWAY

E. Oliveira, S. Quental, F. Ferreira, S. Alves, V. Gomes, A. Amorim, M.J Prata (IPATIMUP, Porto, Portugal)

0026 DASATINIB INDUCES RAPID AND DURABLE RESPONSES IN PATIENTS WITH PH+ ALL RESISTANT OR INTOLERANT TO IMATINIB: UPDATED RESULTS FROM CA180015 (START-L) TRIAL

O. Ottmann, A. Hochhaus, G. Saglio, R. Paquette, B. Simonsson, K. Porkka, J.M.A. Van Tornout, A.M. Apanovitch, P. Rousselot (Johann Wolfgang Goethe Universitaet, Frankfurt Main, Germany)

0027 OUTCOME OF ADULT PATIENTS WITH RELAPSED ACUTE T-LYMPHOBLASTIC LEUKEMIA (T-ALL) CAN BE IMPROVED WITH SEQUENTIAL SALVAGE THERAPIES AND SCT IN SECOND CR

N. Goekbuget, R. Arnold, A. Böhme, R. Fietkau, M. Freund, A. Ganser, M. Kneba, T. Lipp, W.-D. Ludwig, G. Maschmeyer, D. Messerer, H. Rieder, E. Thiel, D. Hoelzer (J.W.Goethe University, Frankfurt Am Main, Germany)

0028 L-ASPARAGINASE HYPERSENSITIVITY IN CHILDHOOD ALL - ISRAEL EXPERIENCE

A. Moser, S. Santo-Zohar, J. Kapelushnik (Soroka Medical Center, Beer Sheva, Israel)

0029 OUTCOME OF THE TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA USING A PEDRIATRIC PROTOCOL

S. Haiat, A. Vekhoff, C. Marzac, O.A. Calendini, S. Lapusan, Z. Marjanovic, B. Rio, J.P. Marie, O. Legrand (Hopital Hotel Dieu, Paris Cedex 04, France)

---

[ Top of page ]

 

ACUTE MYELOID LEUKEMIA - BIOLOGY I

0030 EXPRESSION OF ANGIOPOIETINS AND VASCULAR ENDOTHELIAL GROWTH FACTORS AND ITS CLINICAL SIGNIFICANCE IN ACUTE MYELOID LEUKEMIA: ANG-2 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR OVERALL SURVIVAL

H.-A. Hou, W.-C. Chou, L.-I. Lin, J.-L. Tang, M.-H. Tseng, C.-F. Huang, M. Yao, C.-L. Chen, S.-Y. Huang, C.-Y. Chen, B.-S. Ko, W. Tsay, Y.-C. Chen, H.-F. Tien (National Taiwan University Hospital, Taipei, Taiwan)

0031 MUTATED NUCLEOPHOSMIN (NPM1) IS ASSOCIATED WITH INCREASED SPONTANEOUS APOPTOSIS AND FAVORABLE PROGNOSIS IN FLT3-ITD NEGATIVE ACUTE MYELOID LEUKEMIA (AML)

G. Del Poeta, E. Ammatuna, S. Zaza, F. Buccisano, T. Ottone, I. Del Principe, S. Lavorgna, G. Catalano, F. Luciano, L. Maurillo, L. Ottaviani, A. Bruno, A. Venditti, P. De Fabritiis, S. Amadori, F. Lo-Coco (University Tor Vergata, Rome, Italy) 0032 ACUTE MYELOID LEUKEMIA IS PROPAGATED BY A LEUKEMIC

STEM CELL WITH LYMPHOID CHARACTERISTICS IN A MOUSE MODEL OF CALM/AF10 POSITIVE LEUKEMIA

A. Deshpande, M. Cusan, V.P.S. Rawat, H. Reuter, A. Krause, C. Pott, L. Quintanilla-Martinez, P. Kakadia, F. Kuchenbauer, F. Ahmed, E. Delabesse, M. Hahn, P. Lichter, M. Kneba, W. Hiddemann, E. MacIntyre, C. Mecucci, W.D. Ludwig, R.K. Humphries,

S.K. Bohlander, M. Feuring-Buske, C. Buske (GSF, Munich, Germany) 0033 IDENTIFICATION OF HEME OXYGENASE 1 (HO-1=HSP32) AS A CRITICAL SURVIVAL FACTOR AND NEW THERAPEUTIC TARGET IN AML

M. Kneidinger, K. V. Gleixner, R. Kondo, P. Samorapoompichit, A. Vales, M.-T. Krauth, M. Mayerhofer, A. Gruze, W. F. Pickl, K. Greish, A. Böhm, W. R. Sperr, H. Maeda, P. Valent (Medical University of Vienna, Vienna, Austria)

0034 ABSENCE OF JNK ACTIVATION IS A PREDICTOR OF ANTHRACYCLINE RESISTANCE IN AML

E.D. Lagadinou, P. Ziros, O. Tsopra, K.S. Dimas, E. Thanopoulou, A. Kouraklis-Symeonidis, M. Karakantza, P. Pantazis, N.C. Zoumbos (University Hospital of Patras, Patras, Greece)

0035 DEFINED NICHE CONDITIONS AND A STEM CELL PHENOTYPE BOTH CONTRIBUTE TO THE IN VITRO RESISTANCE OF PRIMARY AML CELLS TO A FLT3 TYROSINE KINASE INHIBITOR

M. Pallis, C.H. Seedhouse, N.H. Russell, U. Mony, M. Jawad

(Nottingham University Hospitals, Nottingham, United Kingdom) 0036 ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA

C.M.S. Conticello, L. Adamo, L. Vicari, R. Giuffrida, G. Iannolo, G. Moschetti, G. Anastasi, G.A. Palumbo, R. De Maria, R. Giustolisi, F. Di Raimondo, M. Gulisano (Istituto oncologico del Mediterraneo, Viagrande, Catania, Italy)

0037 ALLELIC IMBALANCES AND MUTATIONS OF AML1, MLL, AND FLT3 GENES ANALYSIS IN RADIATION-ASSOCIATED ACUTE MYELOID LEUKEMIA

S. Klymenko, J. Smida, M. Atkinson, K. Bink, K. Trott, V. Bebeshko, D. Bazyka, I. Dmytrenko, I. Abramenko, H. Zitzelsberger, M. Rosemann (Research Centre for Radiation Medicine, Kyiv, Ukraine)

0038 INHIBITION OF SDF-1/CXCR4 AXIS AFFECTS SURVIVAL AND DIFFERENTIATION OF HUMAN AML CELLS

S. Tavor, M. Eisenbach, J. Jacob-Hirsch, S. Kay, S. Baron, K. Ben-Zion, N. Amariglio, V. Deutsch, E. Naparstek, G. Rechavi (Sourasky Medical Center, Tel-aviv, Israel)

0039 RETROVIRAL INSERTIONAL MUTAGENESIS SCREEN IN A C/EBPALPHA PROLIFERATIVE GENETIC BACKGROUND

M.S. Hasemann, A.B. Sorensen, F.S. Pedersen, C. Nerlov, B.T. Porse (Copenhagen University Hospital, Copenhagen O, Denmark)

0040 CONSTITUTIVE PI3 KINASE ACTIVATION REPRESENTS A FAVORABLE PROGNOSTIC FACTOR IN DE NOVO AML PATIENTS UNDER 60 YEARS

J. Tamburini, C. Elie, V. Bardet, N. Chapuis, S. Park, P. Broët, P. Cornillet-Lefebvre, B. Lioure, V. Hugo, O. Blanchet, N. Ifrah, F. Witz, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary

(Institut Cochin, Paris, France) 0041 LS104, A NOVEL KINASE INHIBITOR, INDUCES APOPTOSIS, SYNERGIZES WITH CYTOSTATIC DRUGS AND IS TARGETING THE RECEPTOR TYROSINE KINASE FLT3

S. Kasper, F. Breitenbuecher, T. Kindler, F. Heidel, D.B. Lipka, J. Elliot, Ch. Huber, T. Fischer (3rd Medical Department, Mainz, Germany)

0042 CHROMOSOME 21-ENCODED MIR-125B AND ITS ROLE IN THE LEUKEMOGENESIS OF MYELOID LEUKEMIAS IN CHILDREN WITH TRISOMY 21

K. Janikova, J.H. Klusmann, D. Reinhardt (Medical School Hanover, Hanover, Germany)

0043 FUNCTION AND CLINICAL APPLICATION OF EMBRYONIC GENE NANOG IN CANCER

T.H. Lipscomb, L. Zhang, M.A. Karajannis, S. Rafii, D.K. Jin (Weill Medical College, Cornell University, New York, USA)

0044 THE CYTOSOLIC SEQUESTRATION OF NF-KB INDUCED BY DELOCALIZED NPM1 MAY REPRESENT ONE OF THE MECHANISM RESPONSIBLE FOR THE BETTER CHEMOSENSITIVITY OBSERVED IN NPM1 MUTATED AML PATIENTS

D. Cilloni, V. Rosso, F. Messa, E. Messa, S. Carturan, I. Defilippi, F. Arruga, R. Catalano, C. Boveri, C. Bittoto, P. Nicoli, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

0045 THE HOMEOBOX A9 GENE (HOXA9) IS REQUIRED FOR SURVIVAL OF HUMAN MLL-REARRANGED ACUTE LEUKEMIAS

J. Faber, A. Krivtsov, M. Stubbs, R. Wright, M. Van den Heuvel-Eibrink, C. Zwaan, A. Kung, S.A. Armstrong (Children's Hospital Boston, Boston, USA)

---

[ Top of page ]

 

ACUTE MYELOID LEUKEMIA - CLINICAL I

0046 PROGNOSIS OF ACUTE MYELOID LEUKEMIA IN FIRST RELAPSE: IMPORTANCE OF THE HOVON/SAKK INDEX

A. Botelho de Sousa, F. Costa (Hospital dos Capuchos, Lisbon, Portugal)

0047 IMPAIRED NUTRITIONAL STATUS AMONG RUSSIAN AND NORWEGIAN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA

P.O. Iversen, J.M. Tangen, E. Ukrainchenko, F. Wisløff, B. Afanasyev (University of Oslo, Oslo, Norway)

0048 FRACTIONATED DOSES OF GEMTUZUMAB OZOGAMICIN (3,3,3 REGIMEN) IN ADDITION TO ESCALATED DOSES OF DAUNORUBICIN AND CYTARABINE FOR THE REINDUCTION TREATMENT OF RELAPSED AML: A PHASE 1/2 STUDY OF THE ALFA GROUP

H. Farhat, N. Boissel, O. Reman, N. Contentin, S. Corm, E. Raffoux, S. De Botton, P. Rousselot, C. Preudhomme, F. Pousset, S. Chevret, H. Dombret, S. Castaigne (Hopital de Versailles, Le Chesnay, France)

0049 ADDING LOW DOSE GEMTUZUMAB OZOGAMICIN TO FLUDARABINE ARA-C AND IDARUBICIN MAY IMPROVE DFS AND OS IN ELDERLY PATIENTS WITH NON M3 AML: RESULTS OF A PROSPECTIVE, PILOT, TRIAL AND COMPARISON WITH A HISTORICAL COHORT OF PATIENTS

M. Clavio, L. Vignolo, A. Albarello, R. Varaldo, G. Catania, A. Ghiso, C. Ghiggi, F. Olcese, I. Pierri, M. Miglino, A. Manna, E. Balleari, A.M. Carella, M. Sessarego, M.T. Van Lint, A. Bacigalupo, M. Gobbi (Clinica Ematologica Univ. Genova, Genova, Italy)

0050 AN ANTHRACYCLINE FREE REGIMEN BASED ON CONTINUOUS SEQUENTIAL INFUSION OF FLUDARABINE AND CYTARABINE FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. RESULTS FROM A PHASE II STUDY ON 100 PATIENTS

F. Ferrara, M. D'Arco, G. Mele, M. De Simone, D. Laudati, C. Califano, C. Copia, A. Fasanaro, M. Pedata, S. Palmieri (Cardarelli Hospital, Naples, Italy)

0051 FACTORS INFLUENCING THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION

F. Ferrara, M. Annunziata, M.R. D'Amico, S. Palmieri, C. Copia, M. De Simone, F. Pollio, P. Correale, F.P. Tambaro, A. Viola, G. Mele (Cardarelli Hospital, Naples, Italy)

0052 THE DETERMINATION OF LEUKEMIC PHENOTYPE AND MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA BY USING FLOW CYTOMETRY

P. Topcuoglu, K. Dalva, S. Meric, S. Sahin, M. Arat, M. Beksac (Ankara University, Ankara, Turkey)

0053 WILMS' TUMOUR 1 MUTATION IN NORMAL KARYOTYPE AML

P. Virappane, R.E. Gale, R.K. Hills, I. Kakkas, K. Summers, J. Stevens, C.L. Green, C.G. Allen, H. Quentmeier, H. Drexler, A.K. Burnett, D.C. Linch, D. Bonnet, T.A. Lister, J. Fitzgibbon (Institute of Cancer, London, United Kingdom)

0054 ANALYSIS OF NPM1 MUTATIONS USING A SIMPLIFIED DNA-BASED PCR APPROACH DEMONSTRATES THAT ONE THIRD OF YOUNGER ADULT PATIENTS WITH NORMAL KARYOTYPE CARRY A MUTATION

D. Rund, M. Safrai, M. Kedmi, S. Bar Cohen (Hebrew University- Hadassah Hospital, Jerusalem, Israel)

0055 ARE COMORBIDITY SCORES USEFUL DECISION MAKING TOOLS FOR INTENSIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) ?

H. Dombret, J.V. Malfuson, A. Etienne, P. Turlure, T. De Revel, D. Bordessoule, N. Vey, C. Gardin (Hopital Saint-Louis, Paris, France)

0056 PROGNOSTIC SIGNIFICANCE OF FLT3/ITD MUTATION IN PATIENTS WITH AML1/ETO ASSOCIATED ACUTE MYELOID LEUKEMIA

Y.-K. Kim, H.N. Kim, I.K. Lee, D.Y. Jo, J.H. Won, J.H. Choi, S.R. Lee, H.J. Shim, J. S. Ahn, D.H. Yang, J.J. Lee, H.S. Park, H.J. Kim (Chonnam National University Hwasun Hosp, Jeollanam-do, South-Korea)

0057 HAEMORRHAGE AND THROMBOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENTS: RELATION TO THROMBOTIC MARKERS

A. Falanga, D. Balducci, L. Russo, A. Vignoli, M. Marchetti, J.H. Morrissey, T. Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)

0058 FLOW-CYTOMETRIC ASSESSMENT OF MINIMAL RESIDUAL DISEASE DISCRIMINATES CATEGORIES OF RISK AMONG ADULT AML PATIENTS WITH INTERMEDIATE KARYOTYPE

F. Buccisano, L. Maurillo, V. Gattei, G. Del Poeta, M.I. Del Principe, P. Panetta, D. Fraboni, M. Irno Consalvo, S. Campagna, L. Franceschini, L. Ottaviani, C. Sarlo, E. Ammatuna, F. Lo Coco, S. Amadori, A. Venditti (Policlinico Tor Vergata, Rome, Italy)

0059 PROGNOSTIC SCORE INCLUDING SERUM "BETA"-2 MICROGLOBULIN LEVELS TO STRATIFY PATIENTS WITH ACUTE MYELOID LEUKEMIA: ANALYSIS OF 1293 PATIENTS

A.M. Tsimberidou, H.M. Kantarjian, S. Wen, M.J. Keating, S. O'Brien, J. Cortes, S. Pierce, M. Brandt, E.J Freireich, E. Estey (U. T. M. D. Anderson Cancer Center, Houston, USA)

0060 MUTATION PROFILE AND PROGNOSIS OF ADULT ACUTE MYELOID LEUKEMIA WITH INVAGINATED “CUP-LIKE” NUCLEI

A. De Labarthe, O. Nibourel, A. Renneville, V. Biggio, M.T. Daniel, C. Parmentier, J.M. Cayuela, X. Thomas, H. Dombret, C. Preudhomme, N. Boissel (Hopital Saint-Louis, Paris, France)

---

[ Top of page ]

 

ANEMIA AND BONE MARROW FAILURE

0061 GRANULOCYTE TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SEVERE INFECTION

H. Cherif, U. Axdorph, M. Kalin, M. Björkholm (Karolinska University Hospital, Stockholm, Sweden)

0062 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED DONORS IN FANCONI ANEMIA PATIENTS: THE TUNISIAN EXPERIENCE WITH TWO CONDITIONING REGIMENS

L. Torjemane (Centre National de Greffe de Moelle Osse, Tunis, Tunisia)

0063 ALEMTUZUMAB PLUS CYCLOSPORIN A FOR TREATMENT OF PATIENTS WITH BONE MARROW FAILURE SYNDROME

H. Kim, J.-H. Park, S.-J. Shin, Y.J. Min (Ulsan University Hospital, Ulsan, South-Korea)

0064 INCREASED EXPRESSION OF TOLL-LIKE RECEPTOR-4 AND -9 IN THE BONE MARROW OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA MAY CONTRIBUTE TO THE INFLAMMATORY MARROW MICROENVIRONMENT

H. Papadaki, M. Velegraki, K. Pyrovolaki, M. Ximeri, H. Koutala, C. Kalpadaki, G. Gvazava, G. Samonis, G.D. Eliopoulos (University of Crete School of Medicine, Voutes, Heraklion, Greece)

0065 BLOCKADE OF INTRAVASCULAR HEMOLYSIS IN PNH WITH THE TERMINAL COMPLEMENT INHIBITOR ECULIZUMAB UNMASKS LOW-LEVEL HEMOLYSIS POTENTIALLY OCCURRING THROUGH C3 OPSONIZATION

A. Hill, R.P. Rother, A.M Risitano, D.S. Cole, M.J. Cullen, S.J. Richards, C. Selleri, P. Ricci, B. Rotoli, L. Luzzatto, P. Hillmen (Leeds General Infirmary, Leeds, United Kingdom)

0066 HIGH DEFINITION CONTRAST-ENHANCED MR IMAGING IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) SUGGESTS A HIGH FREQUENCY OF SUBCLINICAL THROMBOSIS

A. Hill, S.A. Reid, R.P. Rother, M.T. Gladwin, P.O. Collinson, D.C. Gaze, A. Lowe, A. Guthrie, M.U. Sivananthan, P. Hillmen (Leeds General Infirmary, Leeds, United Kingdom)

0067 THE INCIDENCE AND PREVALENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND SURVIVAL OF PATIENTS IN YORKSHIRE

A. Hill, P.J. Platts, A. Smith, S.J. Richards, M.J. Cullen, Q.A. Hill, E. Roman, P. Hillmen (Leeds General Infirmary, Leeds, United Kingdom)

0068 THIOL-DEPENDENT FORMATION OF LECTIN-INDUCED NEUTROPHIL AGGREGATES

G. Gusakov, I.V. Gorudko (Institute of Applied Physics Problems, Minsk, Republic of Belarus)

0069 HLA-DRB AND –DQB1 GENES IN PREDISPOSITION TO APLASTIC ANEMIA

E. Khamaganova, L. Murashova, Y. Zaretskaya (Research Centre for Hematology, Moscow, Russian Federation)

0070 EXPRESSION OF CD203C ON NEOPLASTIC MAST CELLS IN SYSTEMIC MASTOCYTOSIS: COMPARISON TO NORMAL MAST CELLS AND UPREGULATION BY CROSS-LINKING OF THE FCgRI

A. Hauswirth, L. Escribano, R. Nunez, S. Florian, K. Sonneck, G.-H. Schernthaner, W.R. Sperr, A. Vales, A. Orfao, P. Valent (Medical University of Vienna, Vienna, Austria)

0071 RESULTS OF IMMUNOSUPRESSIVE THERAPY IN CHILDREN WITH SEVERE APLASTIC ANAEMIA. REPORT POLISH PAEDIATRIC LEUKAEMIA AND LYMPHOMA STUDY GROUP

K. Pawelec, M. Matysiak, E. Niewiadomska, J. Stefaniak, J. Kowalczyk, E. Zalecka-Czepko, W. Balwierz, K. Szmyd, A. Chybicka, H.B. Bubala, D. Sonta-Jakimczyk, A. Krauze, A. Kurylak, M. Wysocki, M. Kaczmarczyk-Kanod, J. Wachowiak, I. Karolczyk, M. Stolarska, J. Pergud-Pogorzelski, T. Urasinski, E. Leszczynska, M. Krawczuk-Rybak, M.W Wlazlowski, A. Balcerska (Medical University, Warsaw, Poland)

0072 PHASE II STUDY OF THYMOGLOBULIN, CYCLOSPORINE, AND G-CSF FOR THE INITIAL TREATMENT OF APLASTIC ANEMIA AND LOW RISK MYELODYSPLASTIC SYNDROME

F. Ravandi, S. Faderl, A. Ferrajoli, G. Borthakur, M. Beran, S Pierce, C. Koller, J. Cortes, H. Kantarjian (University of Texas - M.D. Anderson Cance, Houston, USA)

0073 LEAD-INDUCED ANEMIA CAUSED BY THE SAME AYURVEDIC FORMULATION IN BELGIAN PATIENTS

L. Creemers, M. Van den Driessche, M. Moens, A. Van Olmen, M. T’Syen, J. Verschaeren, J. Moerman (Imelda Hospital, Bonheiden, Belgium)

0074 STROMAL CELLS’ ALTERED FUNCTION IN PATIENTS WITH APLASTIC ANEMIA

I. Nifontova, V. Petrova, A. Michaylova, J. Drize (National Hematology Reseach Centre, Moscow, Russian Federation)

0075 ALTERATIONS IN OSTEOBLASTIC AND VASCULAR NICHES REVEALED IN ADHERENT CELL LAYERS OF LONG-TERM BONE MARROW CULTURES FROM PATIENTS WITH APLASTIC ANEMIA

T. Petrova (National Haematology Research Centre, Moscow, Russian Federation)

0076 FURTHER CHARACTERIZATION OF THE CYTOKINE PROFILE IN ACQUIRED APLASTIC ANEMIA

J. Svahn, C. Dufour, E. Ferretti, M. Van Lindt, D. Longoni, M. Pillon, A.P. Iori, F. Bagnasco, U. Ramenghi, A. Bacigalupo, A. Locasciulli, A. Misuraca, M. Lanciotti, S. Pigullo, V Pistoia, V Pistoia, A Corcione (Gaslini Childrens Hospital, Genova, Italy)

0077 HIGH PREVALENCE OF ANAEMIA AMONG FRENCH HOSPITALIZED CANCER PATIENTS: A ONE-DAY CROSS-SECTIONAL SURVEY

S. Castaigne, J.M. Tourani, S. Delaloge, C. Hennequin, M. Zureik, E. Lemarié (Hôpital de Versailles, Le Chesnay, France)

0078 INTRAVENOUS IRON IMPROVES RESPONSE RATES TO RECOMBINANT HUMAN ERYTHROPOIETIN IN ANAEMIC PATIENTS WITH HAEMATOLOGICAL MALIGNANCY ON CHEMOTHERAPY – WHICH IRON PARAMETERS TO USE?

P. Greaves, S. Agrawal, C. Lim, C. Poole (St Bartholomew's Hospital, London, United Kingdom)

0079 SEQUENTIAL MONITORING OF ERYTHROCYTE HEMOGLOBINIZATION AND IRON MARKERS DURING R-HUEPO THERAPY IN ANEMIC PATIENTS WITH MULTIPLE MYELOMA AND LYMPHOMA

E.K. Katodritou, E. Verrou, D. Kapetanos, A. Banti, C. Kartsios, D. Mihou, V. Gastari, D. Markala, S. Effraimidou, A. Lazaridou, E. Terpos, K. Zervas (Theagenion Cancer Center, Thessaloniki, Greece)

0080 RIBOSOMAL PROTEIN S24 GENE ANALYSIS IN DIAMOND BLACKFAN ANEMIA IN ITALY

P. Quarello, E. Garelli, M.F. Campagnoli, A. Carando, A. De Fanti, R. Caruso, I. Dianzani, U. Ramenghi (University of Turin, Turin, Italy)

0081 APLASTIC ANAEMIA: MANAGEMENT CONSTRAINS IN ZARIA, NIGERIA

A. Babadoko, S. Ahmed (University Teaching Hospital, Zaria, Nigeria)

---

[ Top of page ]

 

BLEEDING DISORDERS

0082 ACQUIRED HEMOPHILIA IN URUGUAY (1977- 2007) IN MEMORIAM PROF. ROBERTO DE BELLIS

J. Novoa, R. De Bellis (Ministry of Health, Montevideo, Uruguay)

0083 EXCLUSION OF HAEMOPHILIA A BY DIRECT MUTATION DETECTION IN TRIGEMINI PREGNANCY

A. Bors, H. Andrikovics, K. Hajdu, J. Bátorfi, M. Török, L. Nemes, A. Tordai (National Medical Center, Budapest, Hungary)

0084 HAEMOSTATIC THERAPY DURING SURGICAL OPERATIONS TO HAEMOPHILIA PATIENTS WITH INHIBITOR

T. Polyanskaya, Y. Zorenko, E. Karpov (Hematological Scientific Center, Moscow, Russian Federation)

0085 MANAGEMENT OF HEMOPHILIA IN THREE PREMATURE NEONATES

P. Brons, K. Kraft, R. Verlaak, A. van Heijst (Radboud Univ. Nijmegen Medical Centre, Nijmegen, The Netherlands)

0086 THROMBELASTOGRAPHIC CHART – RELIABLE REFLECTION OF HEMOSTATIC IMPACT OF ITP IN CHILDREN

M. Serban, S. Arghirescu, M. Bataneant, M. Lelik, C. Jinca, E. Boeriu, L. Stana, A. Oprisoni (University of Medicine and Pharmacy, Timisoara, Romania)

0087 EHLERS-DANLOS SYNDROME –A NOT SO UNCOMMON CAUSE OF BLEEDING

S. Dukka, A. Parapia (Bradford royal infirmary, Bradford, United Kingdom)

0088 SUCCESSFUL MANAGEMENT OF AN INFANT WITH KASABACH-MERRITT SYNDROME USING ARTERIAL EMBOLIZATION AND SYSTEMIC DRUG THERAPY

E. Kurekci, B. Ustunsoz, A.A. Atay, N. Balamtekin, D. Hacihamdioglu, Y. Egin (Gulhane Military Medical Academy, Ankara, Turkey)

0089 OFF-LABEL USE OF RFVIIA AND ITS CLINICAL EFFECTIVENESS: RESULTS FROM A SCOTTISH NATIONAL AUDIT

P. Gallipoli, M. Robertson, R.C. Tait (Glasgow Royal Infirmary, Glasgow, United Kingdom)

0090 DISAPPEARANCE OF HIGH TITRE INHIBITOR IN CONGENITAL HEMOPHILIA A USING RITUXIMAB INDUCTION AND MAINTENANCE

M.J.P. Paloma, A.M. Redondo, J.M. Arguiñano, M.A. Ardaiz, M.C. Mateos, Y. Burguete, M.C. Montoya, F.J. Oyarzabal (Hospital Virgen del Camino, Pamplona, Spain)

0091 TYPE 2B 'MALMO OR NEW YORK' IS NOT SO RARE AMONG ITALIAN PATIENTS WITH VON WILLEBRAND DISEASE: THE ROLE OF P1266L/Q MUTATIONS OF THE VON WILLEBRAND FACTOR GENE IN SEVEN CASES

L. Baronciani, S. La Marca, G. Castaman, M. Punzo, B. Moroni, B. Scimeca, V. Rubini, G. Cozzi, M.T. Canciani, A.B. Federici (Hemophilia and Thrombosis Center, Milan, Italy)

0092 EFFICACY AND SAFETY OF HIGHLY PURIFIED VWF/FVIII CONCENTRATES IN THE TREATMENT OF INHERITED VON WILLEBRAND DISEASE: RESULTS FROM THE RETROSPECTIVE ITALIAN STUDY ON 103 CASES

A. Federici, A.B. Federici, M.G. Mazzucconi, G. Barillari, R. Musso, E. Zanon, G. Castaman, R. Targhetta, G. Mancuso, G. Muleo, A. Coppola, M. D'Incà, G. Gamba, C. Latella, A. Borchiellini, L. Valdrè, P. Mannucci (University of Milan, Milan, Italy)

0093 PHARMACOKINETICS OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII (BDD-RFVIII) CONCENTRATE USING CHROMOGENIC AND ONE-STAGE ASSAYS WITH POOLED NORMAL PLASMA (PNP) AND REFACTO LABORATORY STANDARD (RLS)

C. Santoro, M.G. Mazzucconi, P. Pignoloni, A. Rago, F. Biondo, A. Iorio, F. Ferrante, F. Torelli, G. Agnelli, R. Foà (Ematologia, Rome, Italy)

---

[ Top of page ]

 

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY I

0094 GENE EXPRESSION PROFILING OF PERIPHERAL BLOOD T CELLS IN PATIENTS WITH INDOLENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)

K. Kiaii, A. Österborg, K. Mashayekhi, A. Moshfegh, A. Choudhury, H. Mellstedt (Karolinska Institutet, Stockholm, Sweden)

0095 SECONDARY GENETIC EVENTS IN CLONAL CD8+/TCRAB+ LARGE GRANULAR LYMPHOCYTE PROLIFERATIONS

Y. Sandberg, K. Szuhai, D. Tielemans, I. Wolvers-Tettero, E.J. van Gastel-Mol, J.J.M. van Dongen, A.W. Langerak (Erasmus MC, Rotterdam, The Netherlands)

0096 THE MUTATION STATUS OF THE RESIDUAL ATM ALLELE IS AN IMPORTANT DETERMINANT OF TUMOUR PROGRESSION AND PATIENT SURVIVAL IN CLL CASES CONTAINING AN 11Q DELETION

B. Austen, A. Skowronska, J.E. Powell, A. Gardiner, D. Oscier, M. Dyer, A.M. Taylor, P. Moss, T. Stankovic (University of Birmingham, Birmingham, United Kingdom)

0097 HIGH RESOLUTION SNP ARRAYS AND DIFFERENTIAL MIRNA EXPRESSION IDENTIFY NOVEL GENOMIC ABERRATIONS IN CLL

M. Gómez-Benito, C. Vicente, M. Valgañón, E. Bandrés, N. Marcotegui, A. Conchillo, D. Rubio-Felix, M.J. Calasanz, P. Giraldo, M.D. Odero (Center for Applied Medical Research, Pamplona, Spain)

0098 RITUXIMAB SENSITIZES SOME B-CLL SAMPLES TO FLUDARABINE AND CHLORAMBUCIL IN VITRO, REGARDLESS OF P53/ATM STATUS

M. Trbusek, S. Cejkova, L. Rocnova, D. Potesil, J. Chumchalova, J. Smardova, J. Malcikova, P. Kuglik, M. Doubek, Y. Brychtova, S. Pospisilova, J. Mayer (University Hospital Brno, Brno, Czech Republic)

0099 TP53 MUTATION AND 17P DELETION ARE ASSOCIATED WITH POOR SURVIVAL IN PATIENTS WITH CLL IRRESPECTIVE OF THE INACTIVATION OF THE OTHER ALLELE BY DELETION OR TP53 MUTATION: RESULTS FROM A SINGLE CENTER ANALYSIS

T. Zenz, S. Häbe, A. Kröber, A Benner, D. Kienle, A. Bühler, T. Denzel, D. Winkler, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0100 ASSESSMENT OF ZAP-70 EXPRESSION BY FLOW CYTOMETRY USING TWO DIFFERENT ANTIBODIES AND ITS CORRELATION WITH IGVH MUTATION STATUS AND CYTOGENETICS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

W. Kern, F. Dicker, S. Schnittger, C. Haferlach, T. Haferlach (MLL Munich Leukemia Laboratory, Munich, Germany)

0101 IGVH1-69 GENE USAGE IN B-CLL - THE SIGNIFICANCE OF SOMATIC HYPERMUTATION AND CRD3 STRUCTURAL FEATURES

L. Galligan, M.A. Catherwood, T.C.M. Morris, H.D. Alexander (Belfast City Hospital Trust, Belfast, Northern Ireland)

0102 NOTCH2 MIGHT BE INVOLVED IN THE PKC-DEPENDENT SURVIVAL OF B-CLL CELLS

R. Hubmann, M. Hilgarth, S. Schnabl, D. Demirtas, J.D. Schwarzmeier, U. Jaeger, M. Shehata (Medical University of Vienna, Vienna, Austria)

0103 BIALLELIC DELETION 13Q14.3: A NEW PROGNOSTIC MARKER IN CHRONIC LYMPHOCYTIC LEUKEMIA?

C. Chena, J. Sanchez Avalos, G. Arrossagaray, R. Bezares, K. Turdo, A. Bistmans, I. Slavutsky (Instituto de Invest. Hematologicas, Buenos Aires, Argentina)

0104 GELDANAMYCIN HAS OPPOSING EFFECTS ON WILD-TYPE AND MUTANT P53 AND INDUCES P21CIP1 EXPRESSION AND CYTOTOXICITY IRRESPECTIVE OF P53/ATM STATUS IN CHRONIC LYMPHOCYTIC LEUKAEMIA

A.R. Pettitt, G.G. Johnson, P.D. Sherrington, K. Lin (University of Liverpool, Liverpool, United Kingdom)

0105 MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT

J. Malcikova, M. Trbusek, J. Smardova, S. Cejkova, P. Kuglik, Y. Brychtova, M. Doubek, D. Dvorakova, J. Mayer, S. Pospisilova (University Hospital Brno, Brno, Czech Republic)

0106 THE ROLE OF IL-6 IN THE IMMUNE DYSFUNCTION OF B-CLL

G.S. Buggins, P.E.M. Patten, J. Richards, N.S.B. Thomas, G.J. Mufti, S. Devereux (King's College London, London, United Kingdom)

0107 B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) WITH 14Q32 TRANSLOCATIONS: HAEMATOLOGICAL FEATURES AND CLINICAL OUTCOME

F. Cavazzini, J.A. Hernandez, A. Gozzetti, A. Russo Rossi, R. Tiseo, R. Maffei, A. Bardi, E. Tammiso, R. Crupi, M.P. Lenoci, R. Marasca, F. Lauria, G. Torelli, J.M. Hernandez, G.M. Rigolin, A. Cuneo (Section of Hematology, Ferrara, Italy)

0108 COMPREHENSIVE PROTEIN AND RNA EXPRESSION ANALYSIS OF GENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKAEMIA

D. Winkler, C. Schneider, D. Kienle, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0109 DOUBLING TIME OF SOLUBLE CD23 (SCD23DT) ALLOWS TO IDENTIFY A GOOD PROGNOSTIC SUBGROUP IN ZAP+ STAGE A UNTREATED CLL PATIENTS

N. Meuleman, V. Delrieu, B. Stomatopulos, J. Bennani, A. Kentos, P. Heimann, A. Delforge, L. Lagneaux, D. Bron (Institut Jules Bordet, Brussels, Belgium)

0110 HLA-DR ASSOCIATIONS AND CELL CONTACT IMPLICATE SPECIFIC T-CELL RESPONSES IN THE PATHOGENESIS OF SPLENIC MARGINAL ZONE LYMPHOMA

S. Devereux, Z. Davis, A.M. Little, P.E.M. Patten, F. Fowles, J. Richards, D.G. Oscier (Kings College London, London, United Kingdom)

---

[ Top of page ]

 

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL

0111 ZAP-70 MRNA EXPRESSION QUANTIFIED IN B CELLS BY REAL TIME PCR IS A POWERFUL PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, H. Duvillier, M. Massy, P. Martiat, D. Bron, L. Lagneaux (Bordet Institute, Brussels, Belgium)

0112 RITUXIMAB COMBINED WITH CLADRIBINE OR CLADRIBINE AND CYCLOPHOSPHAMIDE IN HEAVILY PRETREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

T. Robak, P. Smolewski, B. Cebula, J.Z. Blonski, O. Grzybowska-Izydorczyk (Medical University of Lodz, Lodz, Poland)

0113 ALEMTUZUMAB AS CONSOLIDATION THERAPY AFTER FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB REGIMEN (FC-R) FOR THE TREATMENT OF YOUNG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

F. Gonnella, A. Carola, M. Esposito, S. Improta, A. Lucania, M.R. Villa, L. Mastrullo (U.O.C. Ematologia, Naples, Italy)

0114 WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?

M. Doubek, E. Cmunt, J. Schwarz, M. Brejcha, M. Heidekerova, M. Trbusek, Y. Brychtova, M. Klabusay, S. Pospisilova, J. Mayer (University Hospital, Brno, Czech Republic)

0115 AUTOLOGOUS TRANSPLANTATION PROLONGS EVENT FREE SURVIVAL AND OVERALL SURVIVAL IN B-CLL PATIENTS WITH B AND C BINET STAGES : RESULTS OF THE PROSPECTIVE GOELAMS LLC 98 TRIAL

P. Feugier, B. Mahé, B. Kolb, B. Audhuy, P. Colombat, H. Maisonneuve, C. Foussard, A. Bureau, A. Brion (CHU Nancy, Vandoeuvre Les Nancy, France)

0116 DIFFERENT PROGNOSTIC GROUPS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) PATIENTS DEFINED BY CD38 AND ZAP-70 EXPRESSION, IG VH GENE STATUS AND GENE EXPRESSION PROFILE

F. Morabito, G. Cutrona, K. Todoerti, M. Spriano, E. Rossi, V. Callea, S. Fabris, S. Matis, M. Gentile, M. Lionetti, G. Festini, E. Vigna, S. Zupo, G. Lambertenghi Deliliers, S. Molica, A. Neri, M. Ferrarini (UOC di Ematologia, Cosenza, Italy)

0117 LONG TERM FOLLOW UP OF HAIRY CELL LEUKEMIA (HCL) PATIENTS TREATED WITH INTERFERON-ALPHA (IFN-a). THE IMPORTANCE OF MAINTENANCE

M. Angelopoulou, K. Anargyrou, S. Sachanas, S. Kokoris, T.P. Vassilakopoulos, Z. Galani, M.N. Dimopoulou, F.N. Kontopidou, E. Plata, P. Tsaftaridis, E. Dimitriadou, M.P. Siakantaris, G.A. Pangalis (University of Athens, Athens, Greece)

0118 THE ACTIVITY OF ALEMTUZUMAB IS INDEPENDENT OF P53 MUTATIONAL STATUS IN FLUDARABINE REFRACTORY CLL: INTERIM ANALYSIS FROM THE CLL2H STUDY OF THE GCLLSG

T. Zenz, S. Häbe, T. Denzel, D. Winkler, A. Kröber, D. Kienle, M. Hallek, M. Hensel, E. Lengfelder, L. Trümper, P. Dreger, U. Jäger, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0119 DOES REDUCED-INTENSITY ALLOGENEIC TRANSPLANTATION CONFER A SURVIVAL ADVANTAGE TO PATIENTS WITH POOR PROGNOSIS CHRONIC LYMPHOCYTIC LEUKAEMIA? A CASE-CONTROL RETROSPECTIVE ANALYSIS

J. Delgado, S. Brunet, G. Pratt, J. Briones, R. Lovell, R. Martino, J. Ewing, D. Valcarcel, A. Sureda, D.W. Milligan, J. Sierra (Hospital Sant Pau, Barcelona, Spain)

0120 PHASE III STUDY OF CLADRIBINE PLUS CYCLOPHOSPHAMIDE COMPARED WITH FLUDARABINE PLUS CYCLOPHOSPHAMIDE FOR PATIENTS WITH PROGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA: REPORT OF PALGCLL3 TRIAL

T. Robak, J.Z. Blonski, J. Gora-Tybor, K. Jamroziak, B. Ceglarek, L. Konopka, M. Calbecka, A. Kostyra, B. Stella-Holowiecka, J. Kloczko, K. Warzocha, I. Seferynska, A. Dmoszynska, M. Kowal, K. Lewandowski, J. Dwilewicz-Trojaczek, G. Charlinski, K. Kuliczkowski, S. Potoczek, A. Hellmann, A. Mital, A. Skotnicki, W.S. Nowak, A. Zdunczyk, J. Dybowicz, K. Sulek, K. Zawilska (Medical University of Lodz, Lodz, Poland)

0121 IMMUNE THROMBOCYTOPENIA IMPAIRS SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

C.V. Visco, R. Stasi, M. Ruggeri, F. Frattini, R Zanotti, A. Ambrosetti, S. Fortuna, I. Giaretta, D. Madeo, G. Pizzolo, F. Rodeghiero (Ospedale S Bortolo, Vicenza, Italy)

0122 CT SCAN GIVES ADDITIONAL INFORMATION OF CLINICAL VALUE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

N.E. Norin, E. Kimby, J. Lundin (Karolinska University Hospital Huddinge, Stockholm, Sweden)

0123 THE COMBINATION OF LUMILIXIMAB AND FCR (FCRL) PRODUCES HIGH RATES OF COMPLETE RESPONSE AND HAS COMPARABLE TOLERABILITY TO FCR IN PATIENTS WITH RELAPSED CLL: RESULTS OF A PHASE I/II STUDY

J.C. Byrd, J. Castro, S. O'Brien, I.W. Flinn, A. Forero-Torres, T.J. Kipps, N.A. Heerema, T. Lin, K. Velastegui, T. Kheoh, A. Molina (Ohio State University, Columbus, USA)

0124 POST-REMISSIONAL RITUXIMAB ADMINISTRATION FOR THE TREATMENT OF OLDER CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS RESPONSIVE TO FIRST-LINE THERAPY WITH CHLORAMBUCIL AND PREDNISONE

F.R. Mauro, I. Del Giudice, M. Gentile, G. De Angelis, M.S. De Propris, M.E. Ghia, M. Marinelli, L. Quattrocchi, P. Fisinger, A. Guarini, R. Foà (Division of Hematology, “La Sapienza” Università, Rome, Italy)

0125 COMBINATION OF IGVH MUTATIONAL STATUS AND GENETIC ABNORMALITIES MAY FURTHER REFINE PROGNOSTIC STRATIFICATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

L. Smolej, M. Hrudkova, P. Zak, D. Belada, S. Pekova, L. Kucerova, J. Schwarz, J. Sobotka, V. Holubova (University Hospital and Medical School, Hradec Kralove, Czech Republic)

0126 THE VALUE OF SERUM BETA 2-MICROGLOBULIN (BETA-2M) IN COMPARISON WITH CD38 AND ZAP-70 EXPRESSION, AND IG VH GENE STATUS IN PREDICTING THERAPY FREE INTERVAL IN EARLY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) PATIENTS

F. Morabito, G. Cutrona, M. Gentile, V. Callea, C. Mazzone, M. Spriano, S. Matis, E. Rossi, G. Festini, A. Neri, S. Molica, M. Ferrarini (UOC di Ematologia, Cosenza, Italy)

0127 PROGRESSION FREE SURVIVAL (PFS) IS SUPERIOR WITH ALEMTUZUMAB VS CHLORAMBUCIL AS FRONT-LINE THERAPY FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (BCLL)

P. Hillmen, A. Skotnicki, T. Robak, B. Jaksic, C. Sirard, J. Mayer (Leeds General Infirmary, Leeds, United Kingdom)

0128 CYTOGENETIC ABNORMALITIES AND ASSOCIATED EFFICACY FROM A PHASE III STUDY COMPARING ALEMTUZUMAB VS. CHLORAMBUCIL AS FIRST LINE THERAPY FOR B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (BCLL)

T. Robak, A. Skotnicki, A. Dmoszynska, J. Hébert, Y. Wang, M. Belkaci, C. Sirard, J. Mayer, P. Hillmen (Kopernik Memorial Hospital, Lodz, Poland)

---

[ Top of page ]

 

CYTOGENETICS AND MOLECULAR DIAGNOSTICS I

0129 PARENTAL ORIGIN DETERMINATION (POD) FISH – A NEW METHOD TO CHARACTERIZE THE PARENTAL ORIGIN OF HUMAN CHROMOSOMES ON A SINGLE CELL LEVEL

M. Gross, H. Mkrtchyan, H. Thieme, F. Von Eggeling, B. Horsthemke, Chr. Jonsrud, U. Claussen, Th. Liehr, A. Weise (Institute of Human Genetics, Jena, Germany)

0130 ALTERATIONS OF THE TP53 IN AML AND CLL ARE STRONGLY ASSOCIATED WITH A COMPLEX ABERRANT KARYOTYPE

C. Haferlach, F. Dicker, H. Herholz, S. Schnittger, W. Kern, T. Haferlach (MLL - Munich Leukemia Laboratory, Munich, Germany)

0131 CHROMOSOME 3 ABERRATIONS IN MYELOID MALIGNANCIES REVEALED BY MOLECULAR CYTOGENETIC TECHNIQUES AND THEIR PROGNOSTIC SIGNIFICANCE

J. Brezinova, Z. Zemanova, L. Babicka, J. Melichercikova, L. Houskova, J. Tajtlova, J. Cermak, M. Siskova, K. Michalova (Institute of Hematology and Blood Transf, Prague 2, Czech Republic)

0132 ANALYSIS OF AML/MDS CELL LINES HIGHLIGHTS GENES TARGETED BY CONCOMITANT 5Q DELETION AND 11Q23 AMPLIFICATION

B. Schneider, S. Nagel, M. Kaufmann, H.G. Drexler, R.A.F. MacLeod (DSMZ, Brunswick, Germany)

0133 ANALYSIS OF 1Q21 COPY NUMBER CHANGES IN PATIENTS IN PROGRESSION AND RELAPSE OF MULTIPLE MYELOMA

J. Balcarkova, V. Scudla, M. Holzerová, H. Pospisilova, M. Zemanova, J. Bacovsky, K. Indrak, M. Jarosova, M. Jarosova (University Hospital Olomouc, Olomouc, Czech Republic)

0134 FREQUENCY AND CLINICAL IMPLICATIONS OF ADDITIONAL CHROMOSOMAL ABERRATIONS IN ETV6/RUNX1 POSITIVE CHILDHOOD ALL

Z. Zemanova, K. Michalova, L Babicka, M. Jarosova, M Holzerova, A. Oltova, M. Hruba, K. Muzikova, J Zuna, J Trka, V. Mihal, J. Sterba, R. Formankova, P. Sedlacek, A. Vrzalova, J. Stary (General Faculty Hospital, Prague 2, Czech Republic)

0135 ROUTINE DETECTION OF CYTOGENETIC ABNORMALITIES IN B-CELL LYMPHOPROLIFERATIVE DISORDERS USING INTERPHASE FISH TECHNIQUES

J.M. O'Connor, S.L. Barrans, K.R. Turner, B.S. Dickinson, A.S. Jack, R.G. Owen (Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

0136 COMPARISON OF PROGNOSTIC IMPACT OF CHROMOSOME 1Q21 GAIN IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY BORTEZOMIB, THALIDOMIDE AND ANY CONVENTIONAL THERAPY

P. Nemec, H. Greslikova, R. Zaoralova, H. Filkova, V. Vranova, R. Kupska, J. Smejkalova, A. Oltova, P. Kuglik, R. Hajek (Myeloma Basic Research Centre, Brno, Czech Republic)

0137 ROUTINE DETECTION OF CYTOGENETIC ABNORMALITIES IN B-CELL LYMPHOPROLIFERATIVE DISORDERS USING INTERPHASE FISH IN PARAFFIN EMBEDDED TISSUE

S. Barrans, K. Turner, S. O'Connor, B. Dickinson, R. Owen, A. Jack (Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

0138 NPM1 HAPLOINSUFFICIENCY IN MDS/AML WITH DEL(5Q)/MONOSOMY 5

R. La Starza, G. Roti, L. Brandimarte, E. Varasano, F. Arcioni, A. Pierini, B. Crescenzi, D. Diverio, G. Guglielmini, M.F. Martelli, A. Aventin, C. Mecucci (Hematology, University of Perugia, Perugia, Italy)

0139 GENETIC PATHWAYS IN LOW- AND HIGH-GRADE HCV-RELATED LYMPHOMAS ARE DIFFERENT

C. Matteucci, M. Bracci, G. Barba, M. Carbonari, M. Casato, A. Pulsoni, G. Roti, R. La Starza, B. Crescenzi, M.F. Martelli, M. Fiorilli, C. Mecucci (Haematology, University of Perugia, Perugia, Italy)

0140 A PROSPECTIVE STUDY IN PH+ CML PATIENTS: FISH IS EFFECTIVE AS CONVENTIONAL CYTOGENETICS FOR DEFINITION OF CYTOGENETIC RESPONSE TO IMATINIB. CORRELATION WITH MOLECULAR RESPONSE (A GIMEMA WP ANALYSIS)

G. Marzocchi, S. Luatti, M. Amabile, C. Gamberini, C. Baldazzi, M. Stacchini, I. Iacobucci, M. Mancini, A. Cuneo, G. Specchia, S. Kerim, E. Giugliano, U. Giussani, M.G. Grimoldi, E. Abruzzese, C. Mecucci, P. Bernasconi, A. Zaccaria, F. Castagnetti, G. Martinelli, G. Rosti, M. Baccarani, N. Testoni (Institute of Hematology "Seràgnoli", Bologna, Italy)

0141 NUP98 RECOMBINATIONS TARGET CD34+ HEMATOPOIETIC CELLS IN AML AND T-ALL

B. Crescenzi, R. La Starza, P. Gorello, S. Romoli, V. Pierini, L. Van Zutven, B. Beverloo, M. Negrini, M.F. Martelli, C. Mecucci (Haematology, University of Perugia, Perugia, Italy)

0142 PROGNOSTIC SIGNIFICANCE OF COMPLEX KARYOTYPE IN PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN ADULTS

I. Granada, A. Oriol, M. Morgades, C. Bethencourt, R. Parody, J.M. Hernández Rivas, M.J. Moreno, E. Del Potro, M. Tormo, C. Rivas, M.A. Sanz, C. Grande, J. Bueno, E. Abella, I. Heras, J.J. Ortega, J.M. Ribera (Hosp. Germans Trias i Pujol. ICO., Badalona, Spain)

0143 CYTOGENETIC ABNORMALITIES OF BONE MARROW-DERIVED MESENCHYMAL STEM CELL IN LEUKEMIC PATIENTS WHO HAD RECEIVED TOTAL BODY IRRADIATION BEFORE ALLOGENEIC TRANSPLANTATION

S.P. Yeh, C.F. Chiu, C.L. Lin, W.J. Lo, Y.M. Liao, C.C. Lee (China Medical University Hospital, Taichung, Taiwan)

---

[ Top of page ]

 

EPIGENETICS, TRANSCRIPTION AND SIGNALLING

0144 TRANSCRIPTIONAL REGULATION OF SONIC HEDGEHOG EXPRESSION BY NF-kB

S. Fulda, H. Kasperczyk, K.M. Debatin, S. Fulda (University Children's Hospital, Ulm, Germany)

0145 POST TRANSLATIONAL TAX MODIFICATIONS CONTROL CRITICAL CYTOPLASMIC AND NUCLEAR STEPS OF NF-KAPPAB ACTIVATION: UBIQUITYLATED TAX ACTIVATES IKK ON A CENTROSOMEASSOCIATED IKK SIGNALOSOME AND SUMOYLATED TAX MEDIATES THE FORMATION OF RELA-ENRICHED TAX NUCLEAR BODIES AND TRANSCRIPTIONAL ACTIVATION

A. Bazarbachi, Y . Kfoury, R. Nasr, A. Favre-Bonvin, M. El-Sabban, N. Renault, M. Giron, H. El Hajj, E. Chiari, A.G. Mikati, O. Hermine, A. Saib, H. De Thé, C. Pique (American University of Beirut, Beirut, Lebanon)

0146 ARSENIC TRIOXIDE INDUCES ACCUMULATION OF CYTOTOXIC LEVELS OF CERAMIDE IN ACUTE PROMYELOCYTIC LEUKEMIA AND ADULT T-CELL LEUKEMIA/LYMPHOMA CELLS THROUGH DE NOVO CERAMIDE SYNTHESIS AND INHIBITION OF GLUCOSYLCERAMIDE SYNTHASE ACTIVITY

A. Bazarbachi, G. Dbaibo, Y . Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. De Thé (American University of Beirut, Beirut, Lebanon)

0147 INSULIN-LIKE GROWTH FACTOR II: A NOVEL AUTOCRINE GROWTH FACTOR IN THE APOPTOSIS, PROLIFERATION, AND MATURATION OF ERYTHROID PROGENITORS IN UMBILICAL CORD BLOOD

T. Nagatomo, K. Muta (Ehime prefectural Central Hospital, Matsuyama, Japan)

0148 BCL11B KNOCKDOWN LEADS TO APOPTOSIS OF MALIGNANT T-CELLS

K. Dittmann, P. Grabarczyk, K. Dittmann, G.K. Przybylski, M. Depke, U. Völker, J. Bahr, K. Assmus, B. Bröcker, R. Walther, C.A. Schmidt (Universität Greifswald, Greifswald, Germany)

0149 P19 (CDKN2D) PLAYS AN IMPORTANT ROLE IN THE ENDOMITOTIC ARREST LINKED TO THE ACCELERATION OF THE MEGAKARYOCYTE MATURATION

D. Bluteau, R. Guièze, L. Gendre, V. Cordette-Lagarde, D. Baudry-Bluteau, R. Favier, N. Debili, W. Vainchenker, H. Raslova (Inserm U790, Villejuif, France)

0150 THE LEUKEMOGENIC CALM/AF10 FUSION PROTEIN ALTERS THE LOCALIZATION OF THE EPIGENETIC REPRESSOR IKAROS

A. Greif, B. Tizazu, A. Krause, E. Kremmer, S.K. Bohlander (GSF / LMU, Munich, Germany)

0151 BRAIN-EXPRESSED X-LINKED-2 (BEX2): EPIGENETIC REGULATION OF A POTENTIAL MARKER FOR ACUTE MYELOID LEUKEMIA WITH MIXED LINEAGE LEUKEMIA REARRANGEMENTS

H. Quentmeier, C. Fischer, J. Reinhardt, M. Zaborski, H.G. Drexler (DSMZ, Braunschweig, Germany)

0152 DOWN REGULATION OF DLX3 EXPRESSION IN MLL/AF4 CHILDHOOD LYMPHOBLASTIC LEUKEMIAS IS MEDIATED BY PROMOTER REGION HYPERMETHYLATION

M. Campo Dell'Orto, B. Banelli, E. Giarin, B. Accordi, L. Trentin, M. Romani, G. Te Kronnie, G. Basso (University of Padua, Padua, Italy) 0153 LBH589, A NOVEL DEACETYLASE INHIBITOR (DACI), IN THE

TREATMENT OF CUTANEOUS T-CELL LYMPHOMA (CTCL): CHANGES IN TUMOR GENE EXPRESSION PROFILES RELATED TO CLINICAL RESPONSE AFTER THERAPY

Y. Pan, H.M. Prince, J. George, R.W. Johnstone, L. Ellis, C. McCormack, G.K. Smyth, R. Williams-Truax, P. Atadja, D. Butterfoss, M. Dugan, K. Culver (Peter MacCallum Cancer Centre, East Melbourne, Australia) 0154 WNT PATHWAY MUTATIONS IN ACUTE LEUKEMIA PATIENTS M. Sayitoglu, O. Hatirnaz, F. Atalar, Y. Erbilgin, U. Ozbek (Istanbul University, Istanbul, Turkey)

0155 WNT5A GENE EXPRESSION AND PROMOTER METHYLATION IN ACUTE LEUKEMIA PATIENTS

O. Hatirnaz, M. Sayitoglu, F. Atalar, Y. Erbilgin, U. Ozbek (Istanbul University, Istanbul, Turkey)

0156 ONCOGENETIC FUNCTION OF KTS+ ISOFORM OF WT1 IN ACUTE AND CHRONIC LEUKEMIAS

D. Cilloni, I. Defilippi, S. Carturan, F. Messa, V. Rosso, F. Arruga, R. Catalano, C. Bittoto, C. Boveri, E. Messa, P. Nicoli, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

0157 ANKHD1 PROTECTS LEUKEMIA CELLS FROM APOPTOSIS AND BINDS TO SIVA, A PROAPOPTOTIC PROTEIN

FT Traina, P.R.M. Lima, F.F. Costa, S.T.O. Saad (State University of Campinas, Campinas, Brazil)

---

[ Top of page ]

 

GENOMICS AND PROTEOMICS

0158 PLASMA PROTEOMIC PROFILES MAY PREDICT EARLY ACUTE GRAFT-VS.-HOST DISEASE (AGVHD) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HLA-IDENTICAL SIBLING TRANSPLANTATION (ALLO-SCT)

M. Mohty, A. Goncalves, E. Esterni, Y. Toiron, B. Gaugler, C. Faucher, J. El-Cheikh, S. Furst, J.A. Gastaut, P. Viens, D. Olive, C. Chabannon, J.P. Borg, D. Blaise (Institute Paoli – Calmettes, Marseilles, France)

0159 PROTEOME PROFILING IDENTIFIES APOLIPOPROTEIN A1 AS A SERUM MARKER CORRELATED TO JAK2 V617F BURDEN IN POLYCYTHEMIA VERA AT DIAGNOSIS

P. Mossuz, A. Bouamrani, S. Brugière, M. Arlotto, S. Hermouet, E. Lippert, F. Laporte, F. Girodon, I. Dobo, V. Praloran, J. Garin, J.Y. Cahn, F. Berger (CHU Grenoble, Grenoble, France)

0160 GRAFT VERSUS HOST DISEASE AND OTHER COMPLICATIONS CAN BE DEPICTED BY SPECIFIC PROTEOMIC PATTERNS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

E. Mischak-Weissinger, E. Schiffer, B. Hertenstein, M. Stadler, E. Holler, J.L. Ferrara, H.J. Kolb, A. Zander, A. Ganser (Hanover Medical school, Hanover, Germany)

0161 MOLECULAR STUDY OF PORTUGUESE PATIENTS WITH CLINICAL DIAGNOSIS OF SHWACHMAN-DIAMOND SYNDROME

E. Costa, J. Oliveira, E. Vieira, F. Duque, P. Garcia, I. Gonçalves, L. Diogo, J. Barbot, R. Santos (Instituto Politécnico de Braganaç, Bragança, Portugal)

0162 METHYLATION PROFILE IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

D. Marinitch, N.D. Volcovets, D.G. Tsvirko, Y.L. Buryanov, T.V. Shevtchuk, O.V. Dyachenko (Byelorussian Hematology Center, Minsk, Republic of Belarus)

0163 IDENTIFICATION OF NEW PROTEINS INVOLVED IN THE PATHOGENESIS OF THE ANTIPHOSPHOLIPID SYNDROME BY PROTEOMIC ANALYSIS: EFFECTS OF IN VIVO STATINS TREATMENT

C. Lopez-Pedrera, M.J. Cuadrado, V.H. Hernandez, M.A. Khamashta, P. Buendia, M.A. Aguirre, N. Barbarroja, L.A. Torres, F. Velasco (Reina Sofia Hospital, Cordoba, Spain)

0164 EVALUATION OF „MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION“ (MLPA) TO DETECT GENOMIC DELETIONS IN CHRONIC LYMPHATIC LEUKEMIA – A COMPARISON WITH CYTOGENETICS, FISH AND PCR

P. Irnstorfer, R. Marschon, S. Heuritsch, K. Enzenhofer, S. Hochreiter, G. Webersinke (Krankenhaus der Barmh. Schwestern, Linz, Austria)

0165 HEMOCHROMATOSIS GENOTYPES AND RISK OF 31 DISEASE ENDPOINTS - META-ANALYSES INCLUDING 66,000 CASES AND 226,000 CONTROLS

C. Ellervik, H. Birgens, A. Tybjærg-Hansen, B.G. Nordestgaard (Herlev Hospital,University of Copenhagen, Herlev, Denmark)

0166 IDENTIFICATION OF HISTONES H2B AND H4 OVEREXPRESSION IN MANTLE CELL LYMPHOMA BY MASS SPECTROMETRY-BASED PROTEOMIC STUDY

D. Rolland, A. Bouamrani, A. Barbarat, M. Arlotto, F. Berger, P. Felman, S. Brugière, J. Garin, R. Houlgatte, F. Berger, C. Thieblemont (INSERM

U836 (équipe 7), Grenoble, France) 0167 HIGH FREQUENCY OF MICROSATELLITE INSTABILITY (MSI) IN LYMPHOID TUMOUR CELL LINES

A. Siebert, C. Mielke, S. Fähnrich, Y. Merkhoffer, H.G. Drexler, W.G. Dirks (DSMZ, Braunschweig, Germany)

0168 METALLOPROTEINASE POLYMORPHISMS IN PH-NEGATIVE CHRONIC MIELOPROLIFERATIVE DISORDERS: NEW GENETIC FACTORS?

M.L. Biondi, G.V. Melzi d'Eril, F. Pateri, L. Ferri, M. Erario, G. Fontana, N.N. Fantini, G.C. Gerli (Laboratorio Chimica-Clinica e Microbiolo, Milan, Italy)

0169 NEW DATA ON ROBUSTNESS OF GENE EXPRESSION SIGNATURES IN LEUKEMIA: COMPARISON OF THREE DISTINCT TOTAL RNA PREPARATION PROCEDURES

M. Campo Dell'Orto, A. Zangrando, L. Trentin, R. Li, W. Liu, G. Te Kronnie, G. Basso, A. Kohlmann (University of Padua, Padua, Italy)

0170 GENOMIC IMBALANCE PROFILES IN MAJOR SUBSETS OF B-NHL: A DESCRIPTIVE META-ANALYSIS OF 1831 PUBLISHED CASES ANALYZED BY CGH M. Baudis (RWTH Aachen University, Aachen, Germany) 0171 EVI1 OVEREXPRESSION IN A SERIE OF 212 HEMATOLOGICAL MALIGNANCIES

H. Luzardo, M.T. Gomez-Casares, J.D. Gonzalez-San Miguel, J. Lopez-Brito, J.M. Calvo-Villas, A. Molines, S. De La Iglesia, A. Caballero, C.E. Lopez-Jorge, G. Santana, A. Suarez, T. Molero (Hospital u. de Gran Canaria Dr. Negrin, Las Palmas De G.c., Spain)

0172 SNP ARRAY PROFILING OF FOLLICULAR LYMPHOMA REVEALS NOVEL REGIONS OF ACQUIRED UPD

D. O'Shea, S. Iqbal, E. Carlotti, A. Davies, T. Chaplin, J. Matthews, M. Manoj, A. Norton, J. Fitzgibbon, T.A. Lister, B.D. Young (CRUK, London, United Kingdom)

0173 INCREASED LEVEL OF B-CATENIN MRNA AND MUTATIONAL ALTERATIONS IN APC GENE ARE PRESENT IN ACUTE LEUKEMIA

F. Atalar, M. Sayitoglu, O. Hatirnaz, Y. Erbilgin, U. Ozbek (Istanbul University, DETAE Genetics Dept, Istanbul, Turkey) 0174 RELATION BETWEEN LOW PML-RARa LEVELS, FLT3-ITD,

OVEREXPRESSION OF CXCR4 GENE AND UNFAVORABLE PROGNOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA

M.C. Chillón, C. Fernández, C. Santamaría, R. García-Sanz, A. Balanzategui, P. Martín-Jiménez, A. Armellini, M. Alcoceba, M.E. Sarasquete, M. Vargas, F. Ramos, L. Guerras, M. González, J.F. Jesús Fernando (Hospital Universitario de Salamanca, Salamanca, Spain)

---

[ Top of page ]

 

HODGKIN'S LYMPHOMA

0175 THE VALUE OF IMMUNOHISTOCHIMICAL EXPRESSION OF P53 AND KI67 AND AGNOR IN HODGKIN’S LYMPHOMA

A. Al-khazraji, F. Helmi (Al Doha University, Ajloun, Jordan)

0176 TREATMENT APPROACH OVERPOWERS IPI PROGNOSTIC SIGNIFICANCE IN HODGKIN'S DISEASE

S. Trpkovska Terzieva, A. Stojanovic, Z. Stojanovski, S. Trajkova, T. Sotirova, S. Genadieva-Stavric, A. Latifi, S. Stankovic, O. Karanfilski (University Clinical Center, Skopje, Macedonia)

0177 ADDING RADIOTHERAPY TO CHEMOTHERAPY DOES NOT IMPROVE OUTCOME OF PATIENTS WITH STAGE I-II HODGKIN’S LYMPHOMA: RESULTS OF A RETROSPECTIVE ANALYSIS OF A REGIONAL ITALIAN EXPERIENCE

F. Olcese, M. Clavio, E. Rossi, M. Spriano, M. Balocco, F. Ballerini, L. Canepa, I. Pierri, S. Aquino, R. Varaldo, A. Manna, V. Secondo, P. Carrara, O. Racchi, E. Balleari, S. Napoli, A.M. Carella, R. Ghio, M. Gobbi (Clinica Ematologica Univ. Genova, Genova, Italy)

0178 REFRACTORY AND RELAPSED HODGKIN’S LYMPHOMA: PRELIMINARY RESULTS OF THE BEACOPP REGIMEN

E. Cavalieri, A. Matturro, N. Frattarelli, S. Tempera, C. Petroni, R. Foà, A. Pulsoni (Hematology, La Sapienza University, Rome, Italy)

0179 ESHAP VS GIN AS SALVAGE AND MOBILIZING REGIMENS IN RELAPSED OR REFRACTORY HL

P. Tsirkinidis, T.P. Vassilakopoulos, M. Moschogiannis, Z. Galani, K. Anargyrou, S. Masouridis, F. Kontopidou, S. Sachanas, E. Dimitriadou, V. Kalotychou, C. Kalpadakis, A. Antoniadis, E. Prassas, D. Chasiotis, E. Variami, N.-A. Viniou, S. Kokoris, M. Siakantaris, Y. Rombos, G.A. Pangalis, M. Angelopoulou (University of Athens, Athens, Greece)

0180 PROGNOSTIC ROLE OF MUM1/IRF4 IN CLASSICAL HODGKIN LYMPHOMA

S. Valsami, V. Pappa, D. Rontogianni, F Kontsioti, E. Papageorgiou, J Dervenoulas, T. Karmiris, N. Harhalakis, S. Papageorgiou, P. Tsirigotis, I Kaitsa, N. Xiros, E. Nikiforakis, T. Economopoulos (2nd Dep. Internal Medicine,Attikon Hosp, Athens, Greece) 0

181 CHOP21 FOR HODGKIN'S LYMPHOMA. AN EXPLORATORY EVALUATION IN COMPARISON TO ABVD AT A SINGLE INSTITUTION

J. Walewski, J. Tajer, E. Lampka, E. Kraszewska, W. Osiadacz, J. Meder (MSCM Institute and Cancer Centre, Warsaw, Poland)

0182 EXPRESSION OF ANGIOGENESIS RELATED FACTORS IN HODGKIN'S LYMPHOMA

F.H. Passam, M. Kafousi, M. Foteinou, G. Tsirakis, P. Roussou, D.S. Kyriakou, M.G Alexandrakis, E. Stathopoulos (Sotiria Hospital, Athens, Greece)

0183 EARLY INTERIM FDG-PET SCAN IN LOCALISED HODGKIN LYMPHOMA: EVALUATION IN 5 FRENCH CENTERS

M.S. Dilhuydy, P. Brice, T. Traulé, P. Solal-Celigny, S. Hirt, A. Pariente, O. Fitoussi (CHU de Bordeaux, Pessac Cedex, France)

---

[ Top of page ]

 

IMMUNOLOGY AND GENE THERAPY

0184 EARLY RECOVERY OF THYMUS-DERIVED NAÏVE T CELLS AND OF NK CELLS IN PEDIATRICS PATIENS AFTER T-CELL DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR THALASSEMIA

A. Isgrò, A. Isgrò, P. Sodani, M. Marziali, P. Polchi, B. Erer, J. Gaziev, K. Paciaroni, A. Roveda, L. Spitaleri, W. Leti, M. Campagna, F. Aiuti, G. Lucarelli (Mediterranean Institute of Hematology, Rome, Italy)

0185 VACCINATION WITH DENDRITIC CELLS: CELLULAR IMMUNE MODULATION BY LEUKOCYTAPHERESIS IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA

M. Hendelmeier, A. Oehring, M. Erdmann, J. Doerrie, N. Schaft, E. Kohler, R. Zimmermann, E. Strasser, R. Eckstein (Transfusion Medicine, Erlangen, Germany)

0186 PROGNOSIS AFTER UNMANIPULATED HLA HAPLOIDENTICAL BLOOD AND MARROW TRANSPLANTATION IS CORRELATED TO THE NUMBERS OF KIR LIGANDS IN RECIPIENTS

X.-J. Huang, X.-Y. Zhao, K.-Y. Liu, L.-P. Xu, D.-H. Liu (Peking University Institute of Hematology, Beijing, China)

0187 DENDRITIC-LEUKEMIA CELL HYBRIDS GENERATE SPECIFIC ANTI LEUKEMIA CTLS IN VITRO

R. Eshel, M. Shpringer, R. Ben-Yosef, A. Vexler, E. Naparstek (Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel)

0188 TOLL-LIKE RECEPTOR EXPRESSION ON TRANSPLANTED T-CELL SUBSETS INFLUENCES OUTCOME AFTER ALLOGENEIC UNRELATED STEM CELL TRANSPLANTATION

U. Platzbecker, J. Stoehlmacher, C. Pabst, Ch. Thiede, G. Ehninger, M. Bornhauser (Universitätsklinikum Carl Gustav Carus, Dresden, Germany)

0189 GENETIC LABELING OF HUMAN CD34-POSITIVE HEMATOPOIETIC PROGENITOR CELLS (HPC) AND MESENCHYMAL STEM CELLS (MSC) BY HIGHLY EFFICIENT mRNA-BASED GENE TRANSFER

J. Greiner, J. Torzewski, P. Ponsearts, M. Rojewski, D. Kronawitter, H. Schrezenmeier, V. Hombach, H. Döhner, M. Schmitt, M. Wiesneth, O. Zimmermann, J. M. Wiehe (University of Ulm, Ulm, Germany)

0190 SELECTIVE DEPLETION OF ALLOANTIGEN-REACTIVE T CELLS BY TRYTOPHAN CATABOLITE 3-HYDROXYANTHRANILIC ACID

S.K. Seo, Y.D. Joo, S.-M. Lee, I.-H. Choi (Inje University College of Medicine, Busan, South-Korea)

0191 IMPROVING THE CLINICAL APPLICABILITY OF CHIMERICRECEPTOR TRANSDUCED T CELLS: CD20 AS A MARKER FOR SELECTION, TRACKING AND ANTIBODY-MEDIATED KILLING OF TRANSDUCED CELLS

V. Marin, H. Kakuda, A. Tintori, A. Biondi, G. D'Amico, D. Campana (M.Tettamanti Research Center, Monza, Italy)

0192 DNA VACCINE AND ALL-TRANS RETINOIC ACID COMBINED TREATMENT ELICITS SPECIFIC AND PROTECTIVE CELLULAR IMMUNE RESPONSES IN A MOUSE MODEL OF PRE-ESTABLISHED ACUTE PROMYELOCYTIC LEUKAEMIA

R.A. Padua, K. Furugaki, H. Moins-Teisserenc, K. Pokorna, M. Reboul, M.-H. Schlageter, D. Charron, C. Chomienne, M. Pla (Institut Universitaire D'Hematologie, Paris, France)

0193 IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN HEMATOLOGICAL MALIGNANCIES FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION

P. Omede, B. Bruno, M. Gilestro, M. Spagnolo, F. Ferro, M. Ruggeri, M. Brunetti, S. Caltagirone, C. Di Bello, A. Fantauzzo, L. Cimolin, C. Sfiligoi, S. Cena, L. Giaccone, F. Fiore, M. Rotta, R. Sorasio, M. Boccadoro (ASO San Giovanni Battista, Turin, Italy)

0194 USING HSV-TK SUICIDE GENE TRANSFER TO IMPROVE THE SAFETY OF DLI

S. Borchers, E.M. Weissinger, A. Ganser (MHH, Hanover, Germany)

0195 MINOR HISTOCOMPATIBILITY ANTIGEN ALLOREACTIVITY: CLINICAL RELEVANCE OF FUNCTIONAL TESTS

F. Garban, D. Laurin, D. Hannani, M. Pernollet, A. Moine, J. Plumas, J.C. Bensa, J.Y. Cahn (CHU Grenoble, Grenoble, France)

0196 HIGH ALLOREACTIVE POTENTIAL OF SUICIDE GENE EXPRESSING CENTRAL MEMORY T LYMPHOCYTES CULTURED WITH HOMEOSTATIC GAMMA-CHAIN CYTOKINES FOR THE CURE OF HEMATOLOGICAL MALIGNANCIES

S. Kaneko, S. Mastaglio, A. Bondanza, M. Ponzoni, L. Aldrighetti, S. Toma, M. Radrizzani, S. La Seta-Catamancio, F. Ciceri, T. Nagasawa, C. Bordignon, C. Bonini (Scientific Institute San Raffaele, Milan, Italy)

0197 SELECTIVE DEPLETION OF ALLOREACTIVITY AND PRESERVING OF ANTI-TUMOR ACTIVITY OF SPECIFIC T CELL CLONES IN PATIENS WITH LEUKEMIA AND RENAL CARCINOMA

E. Matejkova, Z. Hrotekova, A. Stejskalova, D. Kyjovska, P. Vidlakova, J. Michalek (Masaryk University, Brno, Czech Republic)

0198 WT1 FULL LENGTH PROTEIN VACCINATION SHOWS HIGH IMMUNOGENICITY AND SIGNIFICANT ANTI-TUMOUR ACTIVITY IN THE MOUSE MODEL

D. Cilloni, I. Defilippi, P. Nicoli, A. Roetto, A. Bondi, E. Girola, F. Arruga, F. Messa, S. Carturan, V. Rosso, R. Catalano, R. Taulli, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

0199 DETECTION OF HUMORAL IMMUNE RESPONSES AGAINST WILMS TUMOR GENE (WT1) PRODUCT IN PATIENTS AFFECTED BY HAEMATOLOGICAL MALIGNANCIES

D. Cilloni, P. Nicoli, I. Defilippi, E. Girola, A. Bondi, E. Messa, A. Roetto, S. Carturan, F. Messa, F. Arruga, R. Catalano, V. Rosso, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

0200 GAMMA-GLOBIN GENE TRANS-ACTIVATION IN K562 CELLS BY A SYNTHETIC ZINC-FINGER ACTIVATOR GENE TRANSFER

E. Stavrou, E. Lagadinou, E. Papapetrou, C. Barbas III, N. Zoumbos, A. Athanassiadou (University of Patras, Patras, Greece)

---

[ Top of page ]

 

INFECTION AND SUPPORTIVE CARE I

0201 COMBINATION ANTIFUNGAL THERAPY WITH ECHINOCANDIN AND POLYENE IN IMMUNOSUPPRESSED PATIENTS WITH INVASIVE FUNGAL INFECTIONS FAILING FIRST LINE TREATMENT

L. Pagani, E. Morello, C. Vedovelli, P. Mian, B. Amato, P. Viale (Infectious Diseases Unit, Bolzano, Italy)

0202 HIGH INCIDENCE OF INVASIVE FUNGAL SINUSITIS IN PATIENTS UNDERGOING UNDERGOING INDUCTION THERAPY FOR ACUTE MYELOID LEUKAEMIA OR MYELODYSPLASIA WITH FLUDARABINE AND CYTARABINE (FLA) BASED REGIMENS: A RETROSPECTIVE ANALYSIS

Todd, M.W. Besser, E.J. Gudgin, D.A. Enoch, C. Crawley, J.I.O. Craig, M.S. Young Min, J. Cargill, P. Sartori, H.A. Ludlam, G.A. Follows, R.E. Marcus (Addenbrooke's Hospital, Cambridge, United Kingdom)

0203 ERYTHROCYTE POPULATIONS WITH CD55 AND/OR CD59 DEFICIENCY IN PATIENTS WITH HIV INFECTION AND HEMOPHILIA

A. Sarantopoulos, E. Terpos, A. Kouramba, O. Katsarou, J. Stavropoulos, S. Masouridi, J. Meletis, A. Karafoulidou (Laikon General Hospital, Athens, Greece)

0204 PREVENTION OF OVARIAN DAMAGE DURING CHEMOTHERAPY BY GONADOLIBERINE ANALOGUES ADMINISTRATION

L. Smardova (University Hospital, Brno, Czech Republic)

0205 PEGYLATED G-CSF AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

C. Annaloro, P. Usardi, A. Della Volpe, F. Onida, C. Basilico, G. Lambertenghi Deliliers (Fondazione Ospedale Maggiore Policlinico, Milan, Italy)

0206 POTENTIAL ROLE OF CMV IN THE ONTOGENY OF MONOCLONAL TCR"ALPHA""BETA"(+)/CD4(+) T-LARGE GRANULAR LYMPHOCYTE [LGL] LYMPHOCYTOSIS

R.C. Arancha, A.C. Garcia-Montero, J. Almeida Parra, P. Barcena Carrasco, S. Muñoz-Criado, F. Ruiz-Cabello, A. Orfao (Salamanca University, Salamanca, Spain)

0207 THE IMPACT OF ORAL CANDIDIASIS AND HERPES SIMPLEX VIRUS INFECTION ON CHEMOTHERAPY-INDUCED ORAL MUCOSITIS

Y.K. Chen, P.R. Hsueh, C.L. Kao, Y.C. Chen, M. Yao, S.Y. Huang, W.C. Chou, B.S. Ko, C.Y. Chen, J.L. Tang, W. Tsay, Y.C. Chen, H.F. Tien (National Taiwan University Hospital, Taipei, Taiwan)

0208 CONTRIBUTION OF GALACTOMANNAN DETECTION FOR EARLY DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN DIFFERENT GROUPS OF HEMATOONCOLOGICAL PATIENTS

Z. Racil, I. Kocmanova, B. Wagnerova, M. Lengerova, J. Mayer (University Hospital Brno, Brno, Czech Republic)

0209 INCIDENCE OF INVASIVE ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS: AN ITALIAN PROSPECTIVE MULTICENTER STUDY

N. Mordini, D. Mattei, B. Bruno, A. Busca, B. Allione, F. Carnevale Schianca, R. Sorasio, A. Davit, M. Rotta, D. Rapezzi, M. Boccadoro, A. Levis, M. Aglietta, E. Gallo, A. Gallamini (ASO S.Croce e Carle, Cuneo, Italy)

0210 CMV SPECIFIC TETRAMERS – MONITORING PATIENTS AFTER STEM CELL TRANSPLANTATION

S. Borchers, G. Grabow, S. Luther, A. Ganser, E.M. Weissinger (MHH, Hanover, Germany)

0211 HUMORAL AND CELL MEDIATED RESPONSE TO THE PNEUMOCOCCAL CONJUGATE VACCINE (PREVENAR®) IN PATIENTS WITH MYELOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA

H. Greenfield, R. Borrow, J. Adams, R. Warrington, P. Balmer, J. Cavet, K. Mutton, J.A. Liu Yin (Manchester Royal Infirmary, Manchester, United Kingdom)

0212 DIAGNOSING LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH HAEMATHOLOGICAL MALIGNANCIES: USE OF THE NEW T-CELL INTERFERON-GAMMA RELEASE ASSAYS

A. Ferrari, A. Ferrari, M. Losi, F. Luppi, M. Meacci, B. Meccugni, F. Rumpianesi, R. Marasca, M. Luppi, L. Richeldi, L.M. Fabbri, G. Torelli (Division of Hematology, Modena, Italy)

0213 POLYMORPHISMS WITHIN CHEMOKINE (CCL5, CXCL12) AND CHEMOKINE RECEPTOR (CCR5) GENES AND THEIR ASSOCIATION WITH THE RISK OF EBV REACTIVATION IN PATIENTS AFTER ALLOGENEIC HSCT

A. Lange, D. Duda, A. Gieryng, A. Kuzyk, S. Madej, A. Lange (L.Hirszfeld Inst. of Immunol. Exp. Ther., Wroclaw, Poland)

0214 PULMONARY DISPOSITION OF AMPHOTERICIN B LIPID FORMULATIONS

S. Weiler, H. Vogelsinger, R. Bellmann-Weiler, M. Joannidis, R. Bellmann (Medical University of Innsbruck, Innsbruck, Austria)

0215 TUBERCULOSIS (TBC) FOLLOWING SINGLE-UNIT MYELOABLATIVE UMBILICAL CORD-BLOOD TRANSPLANTATION (UCBT) FOR ADULTS WITH HEMATOLOGICAL MALIGNANCIES

S. Cantero, I. Jarque, G. Sanz, M. Salavert, I. Lorenzo, G. Martin, A. Sempere, P. Montesinos, J. Sanz, L. Algarra, J. Moscardo, R. Renart, F. Gomis, G. Orti, M.A. Sanz (Hospital La Fe, Valencia, Spain)

0216 PALIVIZUMAB TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

F. Sicre, M. Robin, R. Peffault de Latour, R. Porcher, C. Scieux, C. Ferry, V. Rocha, K. Boudjedir, A. Devergie, A. Bergeron, A. Gluckman, E. Azoulay, J. Lapalu, G. Socie, P. Ribaud (Saint Louis Hospital, Paris, France)

0217 TUBERCULOSIS AMONG A COHORT OF 35 PATIENTS WITH BLOOD DISEASES

C. Ulibarrena, E. Lavilla, J.L. Sastre (Complexo Hospitalario de Ourense, Ourense, Spain)

---

[ Top of page ]

 

MYELODYSPLASTIC SYNDROMES I

0218 PRION-LIKE DOPPEL GENE (PRND): A NEW MOLECULAR MARKER POTENTIALLY INVOLVED IN LEUKEMOGENESIS

R. Invernizzi, E. Travaglino, C. Benatti, A. Azzalin, B. Rovati, S. Comincini (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

0219 BIOLOGICAL AND CLINICAL RELEVANCE OF MATRIX METALLOPROTEINASES 2 AND 9 IN ACUTE MYELOID LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES

R. Invernizzi, E. Travaglino, C. Benatti, L. Malcovati, M.G. Della Porta, M. Cazzola (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

0220 PROPOSED MINIMAL DIAGNOSTIC CRITERIA FOR MYELODYSPLASTIC SYNDROMES

P. Valent, H.-P. Horny, C. Fonatsch, U. Germing, P. Greenberg, T. Haferlach, D. Haase, H.-J. Kolb, O. Krieger, M. Loken, A. Van de Loosdrecht, K. Ogata, A. Orfao, M. Pfeilstöcker, B. Rüter, W.R. Sperr, R. Stauder, D.A. Wells, J.M. Bennett (Medical University of Vienna, Vienna, Austria)

0221 STEM CELL CULTURES AS A DIAGNOSTIC TOOL IN MYELODYSPLASTIC SYNDROMES

S. Vercauteren, A. Eaves, C. Eaves, A. Karsan (BC Cancer Research Centre, Vancouver, Canada)

0222 COMPARISON OF IWG 2006 AND IWG 2000 RESPONSE CRITERIA FOR ANEMIA OF MDS IN 419 PATIENTS: THE GFM EXPERIENCE

C. Kelaidi, S. Park, S. Grabar, O. Beyne-Rauzy, F. Picard, D. Vassilieff, V. Coiteux, G. Leroux, P. Lepelley, H. Dombret, M.T. Daniel, S. Cheze, B. Mahé, L. Adès, A. Ferrant, C. Ravoet, N. Vey, M. Escoffre-Barbe, L. Aljassem, F. Dreyfus, P. Fenaux (Hôpital Avicenne, Bobigny, France)

0223 FUNCTIONAL CHARACTERIZATION OF ADULT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME

U. Platzbecker, S. Boxberger, B. Mohr, M. Bonin, G. Ehninger, M. Bornhauser (Universitätsklinikum Carl Gustav Carus, Dresden, Germany)

0224 CLINICAL RELEVANCE OF CYTOGENETIC EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS): A STUDY ON 151 PATIENTS

P. Bernasconi, M. Boni, P.M. Cavigliano, I. Giardini, R. Zappatore, S. Calatroni, B. Rocca, I. Dambruoso, M. Caresana, M. Lazzarino (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0225 T-CELL RECEPTOR (TCR) VBETA CDR3 OLIGOCLONALITY REQUENTLY OCCURS IN CHILDHOOD REFRACTORY CYTOPENIA (MDS-RC)

A. de Vries, M.M. van den Heuvel-Eibrink, A.C.H. de Vries, B. Verhaaf, C.M. Niemeyer, J. Stary, K. Schmiegelow, E.R. van Wering, A. Beishuizen, A.W. Langerak (Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands) 0

226 INVOLVEMENT OF A T-CELL RECEPTOR REPERTOIRE IN THE PATHOGENESIS OF MYELODYSPLASTIC SYNDROMES

T. Momot, J. Koenig, A. Ganser, E.-M. Mischak-Weissinger (Medical School Hanover, Hanover, Germany)

0227 PRACTICAL RECOMMENDATIONS ON THE MANAGEMENT OF HAEMATOLOGICAL ADVERSE EVENTS IN MDS PATIENTS TREATED WITH LENALIDOMIDE

A. Giagounidis, M. Cazzola, P. Fenaux, G. Mufti, P. Muus, U. Platzbecker, G. Sanz, L. Cripe, M. Von Lilienfeld-Toal, R. Wells (St. Johannes Hospital, Duisburg, Germany)

0228 COMPARISON OF HYPOPLASTIC MYELODYSPLASTIC SYNDROME (MDS) WITH NORMO-/HYPERCELLULAR MDS BY INTERNATIONAL PROGNOSTIC SCORING SYSTEM, CYTOGENETIC AND GENETIC STUDIES

T.-C. Huang, Tien, B.S. Ko, C. Hsu, C.-Y. Chen, W. Tsay, J.-L. Tang, S.-Y. Huang, M. Yao, Y.C. Chen, M.C. Shen, C.H. Wang (National Taiwan University Hospital, Taipei, Taiwan)

0229 PRACTICAL RECOMMENDATIONS ON THE MANAGEMENT OF NON-HAEMATOLOGICAL ADVERSE EVENTS IN MDS PATIENTS TREATED WITH LENALIDOMIDE

A. Giagounidis, M. Cazzola, P. Fenaux, G. Mufti, P. Muus, U. Platzbecker, G. Sanz, L. Cripe, M. Von Lilienfeld-Toal, R. Wells (St. Johannes Hospital, Duisburg, Germany)

0230 CORRELATION BETWEEN OCCURRENCE OF CYTOPENIAS AND RESPONSE TO LENALIDOMIDE THERAPY IN DEL 5Q MDS PATIENTS

A. Sekeres, J.P. Maciejewski, A. Giagounidis, K. Wride, R. Knight, A. List (Cleveland Clinic Taussig Cancer Center, Cleveland, USA)

0231 ENDOPLASMIC RETICULUM GENE EXPRESSION PROFILE OF ERYTHROID PROGENITORS IN LOW RISK MYELODYSPLASTIC SYNDROMES

E.G. Gyan, A. Sternberg, S. Leclercq-Cardus, L. Willems, N. Cagnard, E. Frisan, F. Dreyfus, C. Lacombe, P. Vyas, M. Fontenay (Institut Cochin, Paris, France)

0232 ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS AND SAML FOLLOWING FLAMSA- CHEMOTHERAPY, REDUCED INTENSITY CONDITIONING AND PREEMPTIVE DONOR LYMPHOCYTE TRANSFUSION

H.J. Kolb, C. Schmid, M. Schleuning, A. Rank, R. Buhmann, J. Tischer, P. Valent, G. Ledderose (University of Munich, Munich, Germany)

0233 PREFERENTIAL CYTOGENETIC RESPONSE TO LOW-DOSE DECITABINE IN MDS WITH CHROMOSOME 7 ABNORMALITIES

R. Claus, P. Wijermans, B. Rüter, R. Kunzmann, M. Lübbert (University of Freiburg Medical Center, Freiburg, Germany)

0234 DISEASE PROGRESSION IN DEL(5Q) MDS PATIENTS TREATED WITH LENALIDOMIDE: ANALYSIS OF RISK FACTORS AND LONG TERM OUTCOME IN 45 PATIENTS

A. Giagounidis, S. Haase, V. Lohrbacher, B. Schuran, M. Heinsch, C. Aul (St. Johannes Hospital, Duisburg, Germany)

---

[ Top of page ]

 

MYELOPROLIFERATIVE DISORDERS - BIOLOGY

0235 FUSION OF FIP1L1 AND RARA AS A RESULT OF A NOVEL T(4;17) (Q12;Q21) IN A CASE OF JUVENILE MYELOMONOCYTIC LEUKEMIA

A. Buijs, M. Bruin (University Medical Center Utrecht, Utrecht, The Netherlands)

0236 BONE MARROW RENIN-ANGIOTENSIN SYSTEM EXPRESSION IN POLYCYTHAEMIA VERA AND ESSENTIAL THROMBOCYTHAEMIA DEPENDS ON JAK2 MUTATIONAL STATUS

M. Marusic Vrsalovic, V. Pejsa, T. Stoos Vejic, S. Ostojic Kolonic, R. Ajdukovic, V. Haris, O. Jaksic, R. Kusec (Dubrava University Hospital, Zagreb, Croatia)

0237 THE MYELOPROLIFERATIVE DISEADE JAK2 V617F MUTANT CANNOT BE REGULATED BY SOCS PROTEINS

M. Hookham, J. Elliott, Y. Suessmuth, A. Ward, J. Staerk, W. Vainchenker, M. Percy, M.F. McMullin, S. Constantinescu, J. Johnston (Queens University Belfast, Belfast, United Kingdom)

0238 DETECTION OF ACTIVATED STAT5 IN THE CYTOPLASM OF NEOPLASTIC CELLS IN VARIOUS MYELOID NEOPLASMS

K. Sonneck, R. Fritz, L. Müllauer, K.V. Gleixner, M. Mayerhofer, S. Florian, M. Kerenyi, W.R. Sperr, C. Sillaber, R. Moriggl, P. Valent (Medical University of Vienna, Vienna, Austria)

0239 NF-E2 OVEREXPRESSION DELAYS ERYTHROID DIFFERENTIATION AND INCREASES ERYTHROCYTE PRODUCTION

A.S. Magin / M. Mutschler (both authors contributed equally to this work), M. Buerge, B. Will, H. L. Pahl (University Hospital Freiburg, Freiburg, Germany)

0240 STEPWISE TRANSFORMATION OF PRIMARY BONE MARROW PROGENITOR CELLS EX VIVO

M. Scherr, Y. Dogan, G. Beutel, K. Battmer, L. Venturini, D. Schaefer, L. Wilkens, A. Ganser, M. Eder (Hanover Medical School, Hanover, Germany)

0241 A NOVEL ARG371HIS MUTATION IN THE HIF PROLYL HYDROXYLASE PHD2 IS ASSOCIATED WITH ERYTHROCYTOSIS

M.J. Percy, P.W. Furlow, P.A. Beer, T.R.J. Lappin, M.F. McMullin, F.S. Lee (Belfast City Hospital, Belfast, United Kingdom)

0242 CHRONIC IDIOPATHIC MYELOFIBROSIS COMPLICATED BY PULMONARY ARTERIAL HYPERTENSION IS DISTINCTIVELY CHARACTERIZED BY ENDOTHELIAL PROGENITOR CELL INSUFFICIENCY AND INCREASED ANGIOGENESIS

A Cortelezzi, G. Gritti, N. Del Papa, C. Pasquini, M. Cortiana, I. Silvestris, R. Calori, U. Gianelli, C. Vener, F. Sozzi, G. Parati, G. Lambertenghi-Deliliers (University of Milan- IRCCS Policlinico, Milan, Italy)

0243 JAK2V617F AND MPLW515L: PRESENCE OF MYELOPROLIFERATIVE DISEASE (MPD)-ASSOCIATED MUTATIONS DOES NOT NECESSARILY LEAD TO ACTIVATION OF DOWNSTREAM SIGNALLING PATHWAYS

H. Quentmeier, J. Reinhardt, M. Zaborski, H.G. Drexler (DSMZ, Braunschweig, Germany)

0244 JAK2 MUTATIONS (V617F AND EXON 12) IN CHILDREN WITH ERYTHROCYTOSIS

M.L. Randi, M. Scapin, E. Pacquola, E. Duner, R. Scandellari, S. Bonato, M.C. Putti (University of Padua, Padua, Italy)

0245 POTENT AND SELECTIVE INHIBITION OF EEC COLONY FORMATION IN JAK2V617F POLYCYTHEMIA VERA AND THROMBOCYTHEMIA BY LOW DOSES OF ITF2357, A NEW HISTONE DEACETYLASE INHIBITOR

V. Guerini, O. Spinelli, A. Salvi, G. Finazzi, T. Barbui, M. Introna, J. Golay, A. Rambaldi (Ospedali Riuniti of Bergamo, Bergamo, Italy)

0246 A SMALL DELETION AT 20Q13.13 INDICATES NFATC2 AS A CANDIDATE GENE IN ESSENTIAL THROMBOCYTHEMIA

L. Vieira, A. Vaz, P. Matos, M. Nogueira, B. Marques, A.P. Ambrósio, A.M. Pereira, M.G. Da Silva, P. Jordan (Instituto Nacional de Saúde, Lisbon, Portugal)

0247 EVIDENCE THAT OVERPRODUCTION OF CYTOKINES AND OTHER MOLECULES LINKED TO JAK2 ACTIVATION CONTRIBUTES TO ABNORMAL HEMATOPOIESIS IN POLYCYTHEMIA VERA

M. Boissinot, I. Corre, D. Pineau, S. Hermouet, Y. Jacques (Institut de Biologie, Nantes Cedex, France)

0248 COMPARISON OF WHOLE BLOOD VS PURIFIED BLOOD GRANULOCYTES FOR THE DETECTION AND QUANTITATION OF JAK2-V617F

E. Hermouet, S. Hermouet, I. Dobo, E. Lippert, M.-C. Boursier, L. Ergand, F. Perrault-Hu, D. Pineau (Laboratoire d'Hematologie, Nantes, France)

0249 TWO JAK2 V617F MUTATED ALLELES ARE NECESSARY FOR EPO INDEPENDENCE IN POLYCYTHEMIA VERA

S. Dupont, D. Pisani, A. Massé, N. Casadevall, J.L. Villeval, W. Vainchenker, F. Delhommeau (Inserm, Villejuif, France)

0250 INACTIVATION OF SUPPRESSOR OF CYTOKINE SIGNALING-1 AND -3 (SOCS-1 AND -3) AND SH2-CONTAINING PHOSPHATASE-1 (SHP-1) IN PHILADELPHIA-NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS (CMPD)

M. Lunghi, D. Rossi, C. Deambrogi, M. Cerri, S. Rasi, S. Franceschetti, A. Conconi, P. Riccomagno, D. Capello, G. Gaidano (Division of Hematology, Novara, Italy)

0251 CHARACTERIZATION OF DIFFERENTIALLY EXPRESSED MICRORNAS IN GRANULOCYTES FROM PRIMARY MYELOFIBROSIS

P. Guglielmelli, A. Pancrazzi, C. Bogani, L. Tozzi, R. Zini, A. Bosi, R. Manfredini, A.M. Vannucchi (Florence University, Florence, Italy)

---

[ Top of page ]

 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL I

0252 THALIDOMIDE INDUCED IMPOTENCE IS A COMMON BUT FREQUENTLY UNRECOGNIZED COMPLICATION IN MALE HEMATOLOGY PATIENTS

Ph. Murphy, J.R. O'Donnell (Beaumont Hospital, Dublin, Ireland)

0253 BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE (PAD) COMBINATION THERAPY FOLLOWED BY THALIDOMIDE AND DEXAMETHASONE (TD) AS A SALVAGE TREATMENT FOR RELAPSED MULTIPLE MYELOMA (MM): PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY

S.S Lee, J.H. Lee, B.S. Kim, J.S. Chung, Y.D. Joo, H.M. Ryoo, Y.R. Do, J.Y. Jin, H.J Kang, K.W. Lee, M.H. Lee, H. Shim, K. Kim, S.S. Yoon, C. Suh (Asan Medical Center, Seoul, South-Korea)

0254 COMBINATION OF BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE (PAD) FOR PATIENTS WITH ADVANCED MULTIPLE MYELOMA

A. Palumbo, F. Gay, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, P. Falco, A. Larocca, F. D'Agostino, P. Musto, N. Cascavilla, M. Boccadoro (Az. Osp. S. Giovanni Battista, Turin, Italy)

0255 DAILY LOW DOSE THALIDOMIDE PLUS MONTHLY HIGH-DOSE DEXAMETHASONE AS CONSOLIDATION/MAINTENANCE TREATMENT IN ELDERLY MULTIPLE MYELOMA (MM) PATIENTS

M. Gentile, C. Mazzone, C. Iorio, E. Lucia, E. Vigna, F. Mazzei, P. Carnevale, M.G. Bisconte, C. Gentile, F. Morabito (Haematology Unit, Cosenza, Italy)

0256 COMBINATION OF TCD (THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE); AN EFFECTIVE AND SAFE ALTERNATIVE TO CONVENTIONAL VAD (VINCRISTINE, ADRIAMYCIN AND DEXAMETHASONE) AS A FIRST-LINE THERAPY IN MULTIPLE MYELOMA

Y.-K. Kim, J.J. Lee, S.K. Sohn, H.J. Shin, S.R. Lee, H.J. Shim, J. S. Ahn, D.H. Yang, S.H. Cho, I.J. Chung, H.J. Kim (Chonnam National University Hwasun Hosp, Jeollanam-do, South-Korea)

0257 FREE LIGHT CHAIN ASSAYS FOR EARLY DETECTION OF RESISTANCE TO BORTEZOMIB-BASED REGIMENS

R. Hajek, R. Hajek, Z. Cermakova, L. Pour, H. Novotna, V. Maisnar, M. Tichy, Z. Adam, M. Krejci, A. Krivanova, K.H. Havlikova (Czech Myeloma Group, Brno, Czech Republic)

0258 EFFICACY AND SAFETY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND DEFIBROTIDE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS: RESULTS OF A MULTICENTER PHASE I/II TRIAL

A. Palumbo, A. Larocca, C. Rus, F. Gay, D. Rossi, P. Pregno, P. Falco, I. Avonto, V. Magarotto, F. D'Agostino, M. Iacobelli, G. Gaidano, C. Mitsiades, P.G. Richardson, K. Anderson, M. Boccadoro (Az. Osp. S. Giovanni Battista, Turin, Italy)

0259 LIPOSOMAL DOXORUBICIN INCREASES THE ANTI-TUMOR EFFICACY OF LOW DOSE BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE THERAPY IN ADVANCED MULTIPLE MYELOMA

S. Ciolli, F. Leoni, C. Casini, C. Breschi, A. Bosi (Azienda Universitaria Ospedaliera Caregg, Florence, Italy)

0260 FEASIBILITY AND EFFICACY OF BORTEZOMIB RE-TREATMENT IN MULTIPLE MYELOMA

S. Ciolli, F. Leoni, C. Casini, A. Bosi (Azienda Universitaria Ospedaliera Caregg, Florence, Italy)

0261 SALVAGE THERAPY WITH INTRAVENOUS BORTEZOMIB, MELPHALAN AND DEXAMETHASONE IN PREVIOUSLY TREATED MYELOMA PATIENTS

F. Di Raimondo, A. Chiarenza, V. Del Fabro, L. Schinocca, P. Fiumara, G.A. Palumbo, C. Conticello, G. Amato, R. Giustolisi (Hematology Dept, Univ.of Catania, Catania, Italy)

0262 SALVAGE TREATMENT WITH MELPHALAN 100 MG/M2 IN FULMINANT PROGRESSION OF MULTIPLE MYELOMA

R. Hajek, M. Krejci, A. Krivanova, L. Pour, Z. Adam, L. Zahradova, E. Vetesnikova, J. Mayer, J. Vorlicek (Czech Myeloma Group, Brno, Czech Republic)

0263 THALIDOMIDE-DEXAMETHASONE AS EFFECTIVE TREATMENT OF THE FIRST RELAPSE AFTER TANDEM AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS TRANSPLATATION OF MULTIPLE MYELOMA

G. Charlinski, E. Wiater, W. Wiktor-Jedrzejczak, J. Dwilewicz-Trojaczek (Medical University of Warsaw, Warsaw, Poland)

0264 PRACTICAL RECOMMENDATIONS ON THE MANAGEMENT OF VTE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE TREATED WITH LENALIDOMIDE AND DEXAMETHASONE

A. Palumbo, M. Dimopoulos, J. San Miguel, J.L. Harousseau, M. Attal, M. Hussein, S. Knop, H. Ludwig, M. von Lilienfeld-Toal, P. Sonneveld (Az. Osp. S. Giovanni Battista, Turin, Italy)

0265 PRACTICAL RECOMMENDATIONS ON THE MANAGEMENT OF CYTOPENIAS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE TREATED WITH LENALIDOMIDE AND DEXAMETHASONE

A. Palumbo, M. Dimopoulos, J. San Miguel, J.L. Harousseau, M. Attal, M. Hussein, S. Knop, H. Ludwig, M. von Lilienfeld-Toal, P. Sonneveld (Az. Osp. S. Giovanni Battista, Turin, Italy)

0266 PRACTICAL RECOMMENDATIONS ON THE MANAGEMENT OF NON-HAEMATOLOGICAL ADVERSE EVENTS IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE/DEXAMETHASONE

A. Palumbo, M. Attal, M. Dimopoulos, J. San Miguel, J.L. Harousseau, M. Hussein, S. Knop, H. Ludwig, P. Sonneveld, M. von Lilienfeld-Toal, A. Palumbo (Az. Osp. S. Giovanni Battista, Turin, Italy)

0267 PATIENT ELIGIBILITY FOR LENALIDOMIDE/DEXAMETHASONE TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

A. Palumbo, M. Dimopoulos, J. San Miguel, J.L. Harousseau, M. Attal, M. Hussein, S. Knop, H. Ludwig, P. Sonneveld, M. von Lilienfeld-Toal (Az. Osp. S. Giovanni Battista, Turin, Italy)

0268 EARLY BORTEZOMIB TREATMENT IMPROVES RESULTS IN RELAPSED MYELOMA PATIENTS. BETTER SECOND THAN FURTHER LINES

L.F. Casado Montero, I. Cano, C. Calle, M.I. Gómez-Roncero, F. Solano, M.A. Foncillas, D. De Miguel, M.J. Bustos-Medina, A.R. López-Quiñones, J.R. Romero (Hospital Virgen de la salud, Toledo, Spain)

---

[ Top of page ]

 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - PLASMA CELL BIOLOGY

0269 IN VITRO AND IN VIVO ACTIVITY OF THE VEGF INHIBITOR PAZOPANIB IN MULTIPLE MYELOMA

K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. Le Gouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L.N. Pandite, T. Hideshima, D. Chauhan, K.C. Anderson (Dana-Farber Cancer Institute, Boston, USA)

0270 IDENTIFICATION AND CHARACTERIZATION OF HLA CLASS I RESTRICTED T-CELL EPITOPES IN THE PUTATIVE TUMOR ASSOCIATED ANTIGENS P21 ACTIVATED SERIN KINASE 2 (PAK2) AND CYCLIN DEPENDENT KINASE INHIBITOR 1A (CDKN1A)

M. Witzens-Harig, G. Li, M. Hundemer, S. Wolfrum, A.D. Ho, H. Goldschmidt (University of Heidelberg Hospital, Heidelberg, Germany)

0271 CELLULAR IMMUNE RESPONSES AGAINST THE CANCER TESTIS ANTIGEN SPAN-XB IN HEALTHY DONORS AND PATIENTS WITH MULTIPLE MYELOMA

M. Witzens-Harig, C. Frank, M. Hundemer, A.D. Ho, H. Goldschmidt (University of Heidelberg Hospital, Heidelberg, Germany)

0272 CLINICAL RELEVANCE OF SOLUBLE HLA CLASS I IN WALDENSTROM’S MACROGLOBULINEMIA AND IGM MGUS

Th. Gastinne, Y. Sebti, A.-S. Moreau, A. Duhamel, G. Le Friec, V. Coiteux, L. Amiot, S. Poulain, B. Hennache, P. Morel, I.M. Ghobrial, S.P. Treon, T. Facon, E. Zorn, X. Leleu (CHU, Nantes, France)

0273 PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS EXPRESS B7-H1 (PD-L1) AND INCREASE EXPRESSION FOLLOWING STIMULATION WITH IFN-GAMMA AND TLR LIGANDS VIA A MYD88-, TRAF6-, AND MEK-DEPENDENT PATHWAY

B. Quesnel, J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont (CHU Lille, Lille, France)

0274 NEOPLASTIC PLASMA CELLS ARE DEMONSTRABLE AT BONE MARROW SITES DISTANT TO SOLITARY PLASMACYTOMA OF BONE AND PREDICT FOR PROGRESSION TO MULTIPLE MYELOMA

Q. Hill, A.C. Rawstron, J.A. Child, R.M. De Tute, R.G. Owen (Leeds General Infirmary, Leeds, United Kingdom)

0275 INHIBITION OF CELL PROLIFERATION BY LENALIDOMIDE IS ASSOCIATED WITH STIMULATION OF EGR1 TRANSCRIPTIONAL ACTIVITY IN A CHROMOSOME 5 DELETED BURKITT’S LYMPHOMA AND MULTIPLE MYELOMA CELL LINE

A. Gandhi, J. Kang, D. Stirling, P. Schafer (Celgene Corporation, Summit, USA)

0276 DEPLETION OF BLOOD DENDRITIC CELLS (BDC) AND ITS PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH MULTIPLE MYELOMA

S.P. Smolewski, B. Cebula, A. Branicka, O. Grzybowska-Izydorczyk, H. Urbanska-Rys, T Robak (Medical University of Lodz, Lodz, Poland)

0277 HIGH HEPATOCYTE GROWTH FACTOR LEVELS AND LOW THROMBOSPONDIN LEVELS IN MYELOMA PATIENTS CORRELATE CLOSELY WITH POOR POSTRANSPLANT RESPONSE

L. Pour, M. Penka, Z. Adam, L. Kovarova, J. Smejkalova, V. Krizalkovicova, D. Kyjovska, P. Vidlakova, J. Michalek, J. Vorlicek, R. Hajek (1. Laboratory of Experimental Hematology, Brno, Czech Republic)

0278 MULTIPLE MYELOMA PLASMA CELLS SHOW DIFFERENT CHEMOKINE RECEPTOR PROFILES AT SITES OF DISEASE ACTIVITY

L. Trentin, L. Trentin, M. Miorin, M. Facco, I. Baesso, S. Carraro, N. Maschio, M. Bortoli, C. Gattazzo, L. Bonanni, F. Piazza, G. Binotto, R. Zambello, C. Agostini, G. Semenzato (Università di Padova, Padova, Italy)

0279 EVALUATION OF CYTOKINE NETWORK PROBABLY INVOLVED IN EVOLUTION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE INTO MULTIPLE MYELOMA

S. Misso, L. Paesano, M. D'Onofrio, B. Feola, L. Bene, V. Mettivier, G. Fratellanza, E. D'Agostino, S. Marotta, A. Minerva (Hospital "S. Sebastiano and S. Anna", Caserta, Italy) 12th CONGRESS OF THE EHA, FINAL PROGRAM

0280 HIGHLY PRESERVED POLYCLONAL REGULATORY T CELLS (TREGS)CAN DOMINATE EFFECTOR FUNCTIONS IN MULTIPLE MYELOMA PATIENTS

M. Foglietta (Division of Hematology, Turin, Italy)

---

[ Top of page ]

 

NON-HODGKIN'S LYMPHOMA - BIOLOGY

0281 PERSISTENCE OF LYMPH NODE T(14;18) BEARING CELLS IN FOLLICULAR LYMPHOMA PATIENTS IN CLINICAL COMPLETE REMISSION: PROOF OF PRINCIPLE FOR MAINTENANCE THERAPY?

 J. Mayer, A. Janikova, L. Kren, D. Dvorakova, I. Kroupova, J. Smardova, J. Neubauer, I. Vasova (University Hospital Brno, Brno, Czech Republic)

0282 NK-CELL ASSOCIATED RECEPTORS EXPRESSION IN EPSTEIN-BARR VIRUS (EBV)-POSITIVE GAMMA-DELTA T-CELL LINES DERIVED FROM PATIENTS WITH NASAL T-CELL LYMPHOMA AND CHRONIC ACTIVE EBV INFECTION

Y. Zhang (Tokyo Medical University, Tokyo, Japan)

0283 AMPLIFICATION AT 7Q22 IN THE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) CELL LINE SU-DHL-1 TARGETS CYCLINDEPENDENT KINASE 6 (CDK6)

S. Nagel, H. Quentmeier, C. Meyer, M. Kaufmann, H. Drexler, R. MacLeod (DSMZ, Braunschweig, Germany)

0284 LOCALIZED FOLLICULAR LYMPHOMA: SPREAD OF BCL-2/IGH+ CELLS IN THE BLOOD AND BONE MARROW FROM THE PRIMARY SITE OF DISEASE AND POSSIBILITY OF CLEARANCE AFTER INVOLVED FIELD RADIOTHERAPY

A. Pulsoni, I. Della Starza, N. Frattarelli, E. Ghia, E. Carlotti, E. Cavalieri, A. Matturro, S. Tempera, A. Rambaldi, R. Foà (Hematology, La Sapienza University, Rome, Italy)

0285 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS: A SERIES OF 19 PATIENTS

M. Motta, L. Consoli, C. Cattaneo, M. Micheletti, E. Borlenghi, M.A. Capucci, G. Tabellini, S. Parolini, M. Ungari, F. Facchetti, G. Savoldi, P. Mella, G. Rossi (Spedali Civili, Brescia, Brescia, Italy)

0286 THE PROGNOSTIC SIGNIFICANCE OF CELL CYCLE REGULATORY GENES EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMAS

F. Kontsioti, P.V. Pappa, R.D. Rontogianni, P.S. Papageorgiou, E.C. Economopoulou, T.P. Tsirigotis, K.E. Kavada, G.V. Giannopoulou, K.I. Kaitsa, G.K. Girkas, P.E. Papageorgiou, D.J. Dervenoulas, E.T. Economopoulos (Attikon University General Hospital, Athens, Greece)

0287 Z-GUGGULSTERONE DOWNREGULATES SURVIVIN AND INDUCES CELL DEATH IN LARGE B CELL LYMPHOMA CELLS IN VITRO

M. Angelopoulou, K. Lilakos, V. Salpeas, S. Sachanas, T.P. Vassilakopoulos, M.P. Siakantaris, M.N. Dimopoulou, P. Korkolopoulou, P. Panayiotidis, G.A. Pangalis (University of Athens, Athens, Greece)

0288 CD5 POSITIVE SPLENIC MARGINAL ZONE LYMPHOMA: CLINICAL, CYTOLOGICAL, IMMUNOLOGICAL, MOLECULAR AND CYTOGENETICAL FEATURES OF A SERIES OF 35 CASES

M. Baseggio, F. Petinataud, E. Callet-Bauchu, F. Berger, A. Traverse-Glehen, C. Thieblemont, D. Morel, G. Salles, P. Felman (Centre Hospitalier Lyon-Sud, Pierre-Benite, France)

0289 ABERRANT METHYLATION OF SHP-1 (SH2-CONTAINING PHOSPHATASE 1) AND SOCS-1 (SUPPRESSOR OF CYTOKINE SIGNALLING 1) GENES IN IMMUNODEFICIENCY-RELATED LYMPHOMAS

M. Cerri, M. Cerri, C. Deambrogi, D. Rossi, M. Lunghi, P. Zigrossi, V. Spina, L. De Paoli, P. Riccomagno, A. Gloghini, M. Lucioni, D. Capello, M. Paulli, A. Carbone, G. Gaidano (University of Eastern Piedmont, Novara, Italy)

0290 P53 STABILIZATION BY THE MDM2 INHIBITOR NUTLIN-3A INDUCES P53-DEPENDENT CELL CYCLE ARREST AND APOPTOSIS IN ANAPLASTIC LARGE CELL LYMPHOMA

G. Rassidakis, V. Atsaves, E. Drakos, G. Georgakis, L.J. Medeiros, G. Rassidakis (M.D. Anderson Cancer Center, Houston, USA)

0291 PREVALENCE OF CHLAMYDIA PSITTACI INFECTION IN NODAL AND EXTRANODAL NON-HODGKIN LYMPHOMAS

J.M. Ferreri, R. Dolcetti, M. Guidoboni, M.G. Cangi, L. Pecciarini, G.P. Dognini, P.P. Ghia, M. Malnati, E. Pasini, C. Doglioni, M. Ponzoni (San Raffaele Scientific Institute, Milan, Italy)

0292 SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES (VL > 20%) CONSTITUTES A VARIANT OF SPLENIC MARGINAL ZONE LYMPHOMA WITH DISTINCT CLINICO-PATHOLOGICAL AND MOLECULAR FEATURES

M. Baseggio, A. Traverse-Glehen, F. Berger, E. Callet-Bauchu, M. Ffrench, D. Morel, C. Thieblemont, G. Salles, B. Coiffier, P. Felman (Centre Hospitalier Lyon-Sud, Pierre-Benite, France)

0293 PATIENTS WITH AIDS-RELATED LYMPHOMA HAVE HIGHER EPSTEIN-BARR VIRUS VIRAL LOAD THAN THOSE HIV-INFECTED WITHOUT LYMPHOMA

J.T. Navarro, A. Hernández, J. Grau, J. Rodríguez-Manzano, J.L. Mate, M. Morgades, L. Matas, C. Tural, J. Juncà, F. Millá, E. Feliu, J.M. Ribera (Institut Català d'Oncologia-Badalona, Badalona, Spain)

0294 MYCOSIS FUNGOIDES. IMMUNOHYSTOCHEMISTRY ANALYSIS OF LYMPHOID AND MICROENVIREMENT CELLS BY MACROTISSUE ARRAY

C. Del Agua, A. Rubio-Martinez, F Felipo, M.A. Piris, P. Giraldo (HU Miguel Servet, Zaragoza, Spain)

0295 EXPRESSION OF NPM-ALK LEADS TO ONCOGENIC EFFECTS OF JUNB

P. Vesely, P. Staber, C. Fuchs, I. Bambach, S. Schauer, D. Sternberg, L. Kenner, G. Hoefler (Medizinische Universitaet Graz, Graz, Austria)

0296 RITUXIMAB ENHANCES CELL-MEDIATED CYTOTOXICITY IN PATIENTS WITH B-CELL LYMPHOMA: IN VIVO STUDY OF NK/T-LYMPHOCYTES ACTIVITY

V. Prochazka, M. Novak, Z. Pikalova, T. Papajik, K. Indrak (Teaching Hospital, Olomouc, Czech Republic)

---

[ Top of page ]

 

THERAPY OF NON-HODGKIN'S LYMPHOMA

0297 QUALITY OF LIFE IN PATIENTS WITH NON-HODGKINS-LYMPHOMA DURING MAINTENANCE THERAPY WITH THE ANTI-CD20 ANTIBODY RITUXIMAB

M. Witzens-Harig, M. Reiz, C. Heiss, A. Benner, M. Hensel, K. Neben, P. Dreger, A. Krämer, A.D. Ho (University of Heidelberg Hospital, Heidelberg, Germany)

0298 RITUXIMAB MAINTENENANCE THERAPY IN CD20+ B-CELL NON-HODGKIN-LYMPHOMA – FIRST RESULTS OF A MULTICENTER PROSPECTIVE RANDOMISED PHASE II STUDY

M. Witzens-Harig, M. Hensel, J. Schmier, K. Neben, A. Benner, P. Dreger, C. Kuhn, I. Schmidt-Wolf, A. Krämer, A.D. Ho (University of Heidelberg Hospital, Heidelberg, Germany)

0299 PROGRESS IN TREATMENT RESULTS OF CHILDHOOD B - CELL LYMPHOMAS ( B -NHL) IN THE 15 YEARS EXPERIENCE OF POLISH PEDIATRIC LEUKEMIA / LYMPHOMA STUDY GROUP (PPLLSG)

E. Sowinska, B. Kazanowska, G. Wrobel, D. Pazdzior, M. Jelen, J. Maldyk, H. Bubala, A. Dluzniewska, L. Kapuscinska, A. Koltan, S. Popadiuk, K. Roslan, D.B. Sopylo, J. Stefaniak, K. Stefanska (Wroclaw Medical University, Wroclaw, Poland)

0300 RADIOIMMUNOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA WITH I-131-LABELED CHIMERIC ANTI CD20 C2B8 (I-131 RITUXIMAB)

H.J. Kang, Y.H. Park, S. Kim, G.J. Cheon, C.W. Choi, S.M. Lim, S.S. Lee, I.I. Na, B.Y. Ryoo, S.H. Yang, W.S. Kim, K.H. Kim, S.M. Bang, Y.J. Yuh, S.H. Nam (Korea Cancer Center Hospital, Seoul, South-Korea)

0301 RITUXIMAB AND CHLORAMBUCIL AS FIRST LINE TREATMENT OF LOW-GRADE OCULAR ADNEXAL LYMPHOMAS

L. Nassi, L. Rigacci, M. Puccioni, E. Polito, S. Mappa, S. Dal Pozzo, R. Alterini, V. Carrai, B. Puccini, A. Bosi (Careggi Hospital, Fl, Italy)

0302 PHASE I STUDY OF SMILE CHEMOTHERAPY FOR ADVANCEDSTAGE OR RELAPSED / REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA / LEUKEMIA

Y.L. Kwong, M. Yamaguchi, R. Suzuki, W.S. Kim, Y. Hasegawa, K. Izutsu, J. Suzumiya, T. Okamura, S. Nakamura, K. Kawa, K. Oshimi (University of Hong Kong, Hong Kong, China)

0303 RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH FOLLICULAR LYMPHOMA. A COST-EFFECTIVE STRATEGY?

 C. Francisco J., E. Conde, P. Giraldo, J. Gomez Codina, M. Provencio, E. Rios, A. Rueda, C. Rubio-Terres, C. Varela (Hospital Universitario Puerta del Mar, Cadiz, Spain)

0304 ACTIVITY OF SINGLE-AGENT FLUDARABINE IN GASTRIC MALT LYMPHOMA: IMPACT OF T(11;18)(Q21;Q21) IN MOLECULAR RESPONSE RATE

A. Salar, B. Bellosillo, A. Seoane, A. Ferrer, C. Pedro, A. Alvarez-Larrán, S. Serrano, C. Besses (Hospital del Mar, Barcelona, Spain)

0305 RITUXIMAB’S IMPACT ON LARGE B CELL LYMPHOMA TREATMENT (ANALYSIS OF 116 PATIENTS OF A LYMPHOMA UNIT)

J. Alonso, A. Canovas, G. Barreiro (Hospital Cruces.SVS.UPVVizcaya, Bilbao, Spain)

0306 RISK-ADAPTED IMMUNOCHEMOTHERAPY OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT FCGRIIIA OF THE RECEPTOR GENOTYPE IN PATIENTS WITH FOLLICULAR LYMPHOMA

V. Prochazka, S. Rozmanova, M. Jarosova, T. Papajik, K. Indrak (Teaching Hospital, Olomouc, Czech Republic)

0307 90Y-IBRITUMOMAB TREATMENT FOR RELAPSED AND/OR REFRACTORY B CELL TYPE NON-HODGKIN`S LYMPHOMA. MULTIINSTITUTIONAL ARGENTINIAN STUDY

R. Cacchione, J. Dupont, J. Milone, J. Bordone, L. Riera, M. Ardaiz, M. Castro-Rios, M. Iabstrebner, G. Pombo, A. Basso, G. Avila, S. Rodríguez, N. Tartas, J. Plana, G. Garay, D. Riveros, A. Carrasco, F. Bezares (CEMIC, Buenos Aires, Argentina)

0308 RITUXIMAB COMBINED WITH DEXABEAM SALVAGE THERAPY FOLLOWED BY HIGH DOSE THERAPY (HDT) IN PATIENTS WITH RELAPSED OR REFRACTORY B-NHL: FIRST RESULTS OF A PHASE II MULTICENTRE STUDY

G. Hess, F.T. Flohr, S.K. Kirschey, H.W. Wolf, N.F. Frickhofen, W.R. Roesler, H.L. Link, N. B. Basara, N.P: Peter, N.S. Schmitz, E.W. Weidmann, A.G.B Banat, A.S. Schulz, K.K. Kolbe, G.D. Derigs, C.H. Huber (Johannes Gutenberg-University, Mainz, Germany)

---

[ Top of page ]

 

NOVEL THERAPEUTICS AND TARGETED THERAPIES I

0309 FUNCTIONAL CHARACTERISTICS AND GENE EXPRESSION PROFILES OF PRIMARY ACUTE MYELOID LEUKAEMIA CELLS IDENTIFY PATIENT SUBGROUPS THAT DIFFER IN THE SUSCEPTIBILITY TO HISTONE DEACETYLASE INHIBITORS

C. Stapnes, A. Ryningen, K. Hatfield, A.M. Oyan, G.E. Eide, K.H. Kalland, B.T. Gjertsen, O. Bruserud (Institute of Medicine, Bergen, Norway)

0310 TARGETED THERAPY OF ADULT T CELL LEUKEMIA: FROM THE BENCH TO BEDSIDE

A. Bazarbachi, R. Nasr, M. El-Sabban, H. El Hajj, Y . Kfoury, L. Haddad, H. Hasegawa, W. Hall, H. De Thé, O. Hermine (American University of Beirut, Beirut, Lebanon)

0311 THE TYROSINE KINASE INHIBITOR DASATINIB SUPPRESSES IGEDEPENDENT ACTIVATION AND HISTAMINE RELEASE IN BASOPHILS

M. Kneidinger, K. V. Gleixner, A. Böhm, A. Vales, K. Sonneck, S. Florian, M. Weghofer, C. Lupinek, S. Vrtala, R. Valenta, G. Superti-Furga, F.Y. Lee, P. Valent (Medical University of Vienna, Vienna, Austria)

0312 MLN3897, A NOVEL CCR1 INHIBITOR, IMPAIRS OSTEOCLAST FORMATION AND FUNCTION ASSOCIATED WITH DOWNREGULATION OF C-FOS

S. Vallet, N. Raje, K. Ishitsuka, T. Hideshima, I. Breitktreutz, T. Kiziltepe, H. Yasui, S. Pozzi, D. Cirstea, E. Ocio, N. Shiraishi, M. Ladetto, M. Boccadoro, K. Anderson (Dana Farber Cancer Institute, Boston, USA)

 0313 LS104 IS A NOVEL SUBSTRATE INHIBITOR OF MUTANT JAK2 KINASE AND ACTS SYNERGISTICALLY WITH ATP-BINDING-SITE KINASE INHIBITORS IN JAK2 V617F POSITIVE CELLS

D.B. Lipka, L. Hoffmann, S. Kasper, B. Markova, F. Heidel, F. Breitenbuecher, Th. Kindler, R. Levine, G. Gilliland, J. Elliot, Ch. Huber, Th. Fischer (University Hospital Mainz, Mainz, Germany)

0314 LENALIDOMIDE STRONGLY ENHANCES NATURAL KILLER (NK) CELL AND MONOCYTE MEDIATED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) OF RITUXIMAB TREATED CD20+VE CANCER CELLS IN VITRO

L. Wu, M. Adams, P. Schafer, G. Muller, D. Stirling, J.B. Bartlett (Celgene Corporation, Summit, USA)

0315 DASATINIB IS AN EFFECTIVE TREATMENT OF CENTRAL NERVOUS SYSTEM PH-POSITIVE LEUKEMIA

P. Koskenvesa, J. Rimpiläinen, T. Lundan, S. Mustjoki, B. Brethon, H. Hjorth-Hansen, M. Höglund, H. Knutsen, S. Parikh, E. Raffoux, J. Stromsheim, L. Ågren, F. Gruber, L. Strauss, K. Talvensaari, H. Dombret, E. Elonen, R. Paquette, B. Simonsson, C.M. Zwaan, K. Porkka (Helsinki University Central Hospital, Helsinki, Finland)

0316 EFFICACY OF APO010, A FAS-ACTIVATING MOLECULE, IN MULTIPLE MYELOMA

E.M. Ocio, P. Maiso, M. Garayoa, M. Dupuis, A. Pandiella, J.F. San Miguel (Cancer Research Center, Salamanca, Spain)

0317 SIGNIFICANT PRECLINICAL ANTILEUKEMIC ACTIVITY OF THE TYROSINE KINASE INHIBITOR BVT I IN ACUTE MYELOID LEUKEMIA

S. Eriksson, S. Hassan, M. Höglund, R. Larsson, E. Lindhagen, A. Åleskog, A. Löthgren, K. Föhlenhag, A. Jenmalm Jensen, V. Parrow (Uppsala University Hospital, Uppsala, Sweden)

0318 FACTORS DETERMINING CLINICAL ACTIVITY OF THE HISTONE DEACETYLASE INHIBITOR SODIUM VALPROATE IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA

C. Craddock, F. Khanim, J. Arrazi, M. Griffiths, B. Turner, C. Bunce (Queen Elizabeth Hospital, Birmingham, United Kingdom)

0319 GOLD COMPOUND AURANOFIN INDUCES APOPTOSIS IN MYELOMA CELLS VIA TARGETING IL-6 SIGNALING PATHWAY

A. Nakaya, M. Sagawa, A. Muto, H. Uchida, Y. Ikeda, M. Kizaki (Keio University School of Medicine, Tokyo, Japan)

0320 DASATINIB INHIBITS T CELL ACTIVATION AND PROLIFERATION IN A DOSE-DEPENDENT MANNER

R. Weichsel, C. Dix, J. Zezula, E. Greiner, D.A. Price, H. Einsele, R. Seggewiss (University of Wuerzburg, Wuerzburg, Germany)

0321 BOSUTINIB (SKI-606) EXHIBITS CLINICAL ACTIVITY IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CML OR ALL WHO FAILED IMATINIB

T. Brummendorf, J. Cortes, H. Kantarjian, G. Martinelli, D. Liu, T. Fischer, B. Hewes, A.D.G. Volkert, R. Abbas, C. Gambacorti-Passerini (Universitaetsklinikum Hamburg, Hamburg, Germany)

0322 SULINDAC SULFIDE REVERTS THE ACTIVATION OF THE WNTSIGNALING AND ABERRANT SELF RENEWAL INDUCED BY THE AML-ASSOCIATED FUSION PROTEINS PML/RAR AND PLZF/RAR

M. Ruthardt, E. Puccetti, G. Steinert (Klinikum der J. W. Goethe Universität, Frankfurt, Germany)

0323 MTORC1 INHIBITION ACTIVATES PI3K/AKT BY UP-REGULATING THE IGF-R SIGNALLING IN ACUTE MYELOID LEUKAEMIA: RATIONAL FOR INHIBITION OF BOTH PATHWAYS

J. Tamburini, N. Chapuis, V. Bardet, S. Park, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary (Institut Cochin, Paris, France)

0324 DISCOVERY AND PRECLINICAL DEVELOPMENT OF SELECTIVE JAK INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

S. Fridman, J. Li, P. Liu, E. Caulder, E. Crowgey, M. Favata, G. Guoen, Y. Li, M. Covington, J. Rodgers, A. Combs, S. Yeleswaram, R. Newton, P. Scherle, K. Vaddi (Incyte Corporation, Wilmington, USA)

0325 GEMTUZUMAB OZOGAMICIN (MYLOTARG ) AS MAINTENANCE THERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA

N. Cascavilla, C. Bodenizza, A.M. Carella, M. Dell'Olio, A.P. Falcone, M.M. Greco, A. La Sala, S. Mantuano, L. Melillo, E. Merla, M. Nobile, G. Sanpaolo, P. Scalzulli (Hematology "CSS" Hospital, San Giovanni Rotondo, Italy)

---

[ Top of page ]

 

STEM CELL BIOLOGY AND MICROENVIRONMENT

0326 THE SIMILARITIES OF HUMAN MESENCHYMAL STEM CELLS AND PERICYTES

D. Covas, R.A. Panepucci, A.M. Fontes, W.A. Silva-Jr, M.D. Orellana, L. Neder, A.R.D. Santos, L.C. Perez, M.C. Jamur, M.A. Zago (University of S. Paulo, Ribeirao Preto, Brazil)

0327 STUDY OF FUNCTIONAL AND MOLECULAR CHARACTERISTICS OF THREE DIFFERENT BONE MARROW CELL POPULATIONS FOR EXPANSION OF MESECHYMAL STEM CELLS

H. Papadaki, M.C. Kastrinaki, A. Damianaki, V.M. Vlahava, P. Fragioudaki, E. Stavroulaki, G.D. Eliopoulos (University of Crete School of Medicine, Voutes, Heraklion, Greece)

0328 COMPARATIVE ANALYSIS OF ANGIOGENIC CAPACITY OF MONOCYTES AND CD 133+ CELLS IN A MURINE MODEL OF HINDLIMB ISCHEMIA

N. López-Holgado, M. Alberca, F.M. Sánchez-Guijo, J. Almeida, E. Villaron, J.V. Rivas, J.M. López-Novoa, C. Garcia, J.F. Pérez-Fontán, B. Blanco, L.I. Sánchez-Abarca, S. Tabera, J.A. Pérez-Simón, J.F. San Miguel, M.C. Cañizo (University Hospital of Salamanca, Salamanca, Spain)

0329 REGULATION BY TGFß SUPERFAMILY OF HUMAN B LYMPHOPOIESIS IN A NEWLY ESTABLISHED LYMPHOCYTE CULTURE SYSTEM USING HUMAN MESENCHYMAL STEM CELLS AS A SUPPORTIVE MICROENVIRONMENT

M. Ichii, K. Oritani, T. Yokota, I. Takahashi, T. Shirogane, N. Saitoh, R. Tanigawa, Y. Kanakura (Osaka University Graduate School of Medi, Suita, Japan)

0330 MESENCHYMAL STEM CELLS (MSC) REGULATE IMATINIB RESISTANCE: NO EFFECT OF IMATINIB ON MSC CYTOKINE SECRETION

D. Cai, Y . Wang, C. Brendel, A. Neubauer, A. Burchert (Philipps-University of Marburg, Marburg, Germany)

0331 WNT/BETA-CATENIN PATHWAY MODULATES MULTIPOTENCY OF HEMATOPOIETIC STEM/PROGENITOR CELLS REGULATING THE ACTIVITY OF VARIOUS ESSENTIAL TRANSCRIPTION FACTORS

H. Tanaka, I. Matsumura, K. Itoh, T. Nakahata, Y. Kanakura (Biomedical Research and Innovation, Kobe, Japan)

0332 ACUTE MYELOGENOUS LEUKEMIA CELLS CHANGE INTO FIBROBLAST CELLS MORPHOLOGICALLY AND FUNCTIONALLY DURING IN VITRO LONG-TERM CULTURE

H. Tashiro, M. Noguchi, R. Shirasaki, N. Shirafuji (Teikyo University School of Medicine, Tokyo, Japan)

0333 INVOLVEMENT OF TNF-ALPHA IN LEUKAEMIA ONSET AND BONE MARROW TURNOVER

A.S. Cachaço, A.C. Santos, S. Dias (Portuguese Institute of Oncology, Lisbon, Portugal)

0334 EXPRESSION OF SURFACE MARKERS INVOLVED IN CELLCELL- INTERACTIONS, ADHESION AND ACTIVATION ON ENDOTHELIAL PROGENITOR CELLS

M. Satler, K. Klein, R. Koppensteiner, G.H. Schernthaner (Medical University Vienna, Vienna, Austria)

0335 IN VITRO CHARACTERIZATION OF CORD BLOOD MESENCHYMAL STROMAL CELLS (CB-MSC): IMMUNOMODULATORY PROPERTIES AND HAEMATOPOIESIS SUPPORTING ACTIVITY

L.D. Dorotea, M. Gabelli, E. Magro, C. Messina, R. Destro, M.V. Gazzola (Clinica di Oncoematologia Pediatrica, Padova, Italy)

0336 CXCR4+ CIRCULATING PROGENITOR CELLS COEXPRESSING MONOCYTIC AND ENDOTHELIAL MARKERS MAY BE INVOLVED IN THE PATHOGENESIS OF FIBROSIS IN SYSTEMIC SCLEROSIS

F. Lanza, D. Campioni, A. Lo Monaco, S. Moretti, L. Ferrari, M. Fotinidi, A. Lacorte, F. Trotta, A. Cuneo (Hematology Section, Ferrara, Italy)

0337 THE ANABOLIC EFFECTS OF STRONTIUM INCREASE THE NUMBER OF PROGENITOR BUT NOT PRIMITIVE HAEMOPOIETIC STEM CELLS

S. Lymperi, N. Horwood, A. Cope, F. Dazzi (Imperial College London, London, United Kingdom)

---

[ Top of page ]

 

THROMBOSIS I

0338 ANTI- PLASMINOGEN MONOCLONAL ANTIBODY(MC2B8) INHIBITES ANGIOGENESIS

K. Mansouri (Ilam Medical Biology Research Center, Ilam, Iran)

0339 OUTCOMES OF THROMBOLYSIS FOR REPEATED COURSES OF SYSTEMIC TISSUE PLASMINOGEN ACTIVATOR FOR INTRAVASCULAR THROMBOSIS IN CHILDREN

C. Traivaree, L. Brandao, A.K. Chan, S. Williams (Hospital for Sick Children, Toronto, Canada)

0340 ALTERED FIBRIN CLOT STRUCTURE IN PATIENTS WITH ISCHEMIC STROKE ASSOCIATED WITH FORAMEN OVALE

K. Zawilska, A. Undas, P. Podolec, M. Pieculewicz, E. Stepien, I. Jedlinski, M. Duszynska, E. Hanschke (University of Medical Sciences of Poznan, Poznan, Poland)

0341 THE RISK OF PREGNANCY-RELATED VENOUS THROMBOEMBOLISM IN DOUBLE CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN G20210A

T. Battaglioli, V. De Stefano, D. Tormene, L. Valdré, E. Grandone, A. Tosetto, I. Martinelli (IRCCS Maggiore Hospital, Milan, Italy)

0342 INTRACARDIAC THROMBOSIS IN CHILDREN

N. Ozbek, B. Alioglu, B. Atac, Z. Avci, B. Malbora, K. Tokel (Baskent University, Faculty of Medicine, Ankara, Turkey)

0343 COMPARISON OF HEMOSIL™ HOMOCYSTEINE ASSAY WITH ABBOTT IMX IMMUNOASSAY FOR MEASUREMENT OF PLASMA TOTAL HOMOCYSTEINE.

M. Cattaneo, M.L. Zighetti (Ospedale San Paolo, Università di Milano, Milan, Italy)

0344 ROLE OF THE PAI-1 GENE 4G/5G POLYMORPHISM ON PAI-1 LEVEL AND RELATIONS AMONG PAI-1, TNFa AND TGFß LEVELS IN OBESE CHILDREN

N. Ozbek, S. Tulgar Kinik, B. Atac, M. Yüce, A.C. Yazici, H. Verdi (Baskent University, Faculty of Medicine, Ankara, Turkey)

0345 THROMBOSIS IN CHILDREN WITH CARDIAC PATHOLOGY: ANALYSIS OF ACQUIRED AND INHERITED RISK FACTORS

N. Ozbek, B. Alioglu, B. Atac, Z. Avci, B. Malbora, K. Tokel (Baskent University, Faculty of Medicine, Ankara, Turkey)

0346 HEMOSTATIC FACTORS AND MORTALITY IN SEVERE SEPSIS

O. Gutiérrez Pérez, A. Muriel, A. Silvestre, A. Cantalapiedra, P. Martín, J. Tortosa, J. Blanco, L.J. García Frade (Hospital Universitario Rio Hortega, Valladolid, Spain)

0347 THE ANGIOTENSIN-CONVERTING ENZYME INSERTION/DELETION POLYMORPHISM AND SERUM LEVELS OF ANGIOTENSINCONVERTING ENZYME IN VENOUS THROMBOEMBOLISM: DATA FROM A CASE-CONTROL STUDY

C. Ay, P. Bencur, R. Vormittag, T. Sailer, C. Jungbauer, T. Vukovich, M. Mannhalter, I. Pabinger (Medical University Vienna, Vienna, Austria)

0348 NON ADHERENCE TO DOSING GUIDELINES FOR LMWH IN RENAL IMPAIRMENT LEADS TO A HIGH INCIDENCE OF SIGNIFICANT BLEEDING EVENTS - RESULTS OF A PROSPECTIVE AUDIT

W. Marshall, A. Cole, J. Smyth, M. El-Agnaf (Ulster Hospital, Belfast, United Kingdom)

0349 PREGNANCY OUTCOME IN WOMEN WITH THE LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOEMBOLISM (TE)

G. Alguel, G. Kostova, S. Koder, R. Vormittag, R. Simanek, C. Kurz, I. Pabinger (Medical University of Vienna, Vienna, Austria)

0350 JAK2-V617F MUTATION IS PRESENT IN PATIENTS WITH IDIOPATHIC DVT

M.N. Lauw, E.B. Bus, A.F.Y. van Wulfften Palthe, C.H. Homburg, M. Coppens, S. Middeldorp, C.E. van der Schoot, H.R. Koene (Academic Medical Center, Amsterdam, The Netherlands)

0351 A PROPOSAL OF SCORING SYSTEM IN ASSESSMENT OF THROMBOTIC RISK IN CANCER PATIENT. A MONOCENTRIC STUDY

G. Giordano, G. Farina, R. Tambaro, M. Specchia, S. Papini, M. Piunno, C. Antonelli, B. Zappacosta, S. Storti (UCSC Campobasso, Campobasso, Italy)

0352 PLASMA THROMBOMODULIN: A POTENTIAL MARKER FOR PRE-ECLAMPSIA

B. Lwaleed, L. Dusse, M. Carvalho, D. Voegeli, A. Cooper, B. Lwaleed (Southampton University Hospitals NHS Tru, Southampton, United Kingdom)

0353 TISSUE FACTOR AND TOTAL TISSUE FACTOR PATHWAY INHIBITOR IN CORONARY ARTERY DISEASE: CORRELATION WITH THE SEVERITY OF ATHEROMATOSIS

B. Lwaleed, L. Lima, M. Sousa, L. Dusse, M. Lasmar, B. Lwaleed, M. Carvalho (Southampton University Hospitals NHS Tru, Southampton, United Kingdom)

0354 FACTOR V LEIDEN HOMOZYGOUS GENOTYPE IS ASSOCIATED WITH LATE PREGNANCY LOSS IN THE PROCARE-GEHT COHORT

C. Biron-Andreani, Y. Gruel, B. Delahousse, M.-F. Aillaud, I. Juhan, V. Le Cam - Duchez, C. Saladin - Theron, J.Y. Borg, A. Bauters, B. Jude, F. Dutrillaux, F. Vollot, J.-L. Lorenzini, A. Lequerrec, C. Boinot, J.-F. Schved, P.E. Morange (Laboratoire d'hematologie CHU Saint-Eloi, Montpellier, France)

0355 SPONTANEOUS DEEP VEIN THROMBOSIS OF THE UPPER EXTREMITIES: RISK FACTORS AND LONG TERM FOLLOW UP

D. Lechner, C. Wiener, S. Eichinger, A. Weltermann, L. Eischer, P.A. Kyrle (Medical University of Vienna, Vienna, Austria)